<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aspirin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aspirin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Aspirin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8907" href="/d/html/8907.html" rel="external">see "Aspirin: Drug information"</a> and <a class="drug drug_patient" data-topicid="10985" href="/d/html/10985.html" rel="external">see "Aspirin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F137093"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ascriptin Regular Strength [OTC];</li>
<li>Aspercin [OTC];</li>
<li>Aspir-low [OTC] [DSC];</li>
<li>Aspirin Adult Low Dose [OTC];</li>
<li>Aspirin Adult Low Strength [OTC];</li>
<li>Aspirin EC Low Strength [OTC];</li>
<li>Aspirtab [OTC];</li>
<li>Bayer Aspirin EC Low Dose [OTC];</li>
<li>Bayer Aspirin Extra Strength [OTC];</li>
<li>Bayer Aspirin Regimen Adult Low Strength [OTC];</li>
<li>Bayer Aspirin Regimen Children's [OTC];</li>
<li>Bayer Aspirin Regimen Regular Strength [OTC];</li>
<li>Bayer Aspirin [OTC];</li>
<li>Bayer Genuine Aspirin [OTC];</li>
<li>Bayer Plus Extra Strength [OTC];</li>
<li>Bayer Women's Low Dose Aspirin [OTC];</li>
<li>Buffasal [OTC];</li>
<li>Bufferin Extra Strength [OTC];</li>
<li>Bufferin [OTC];</li>
<li>Buffinol [OTC];</li>
<li>Durlaza;</li>
<li>Ecotrin [OTC];</li>
<li>FT Aspirin [OTC];</li>
<li>GoodSense Low Dose [OTC];</li>
<li>Halfprin [OTC] [DSC];</li>
<li>St Joseph Adult Aspirin [OTC];</li>
<li>Tri-Buffered Aspirin [OTC];</li>
<li>Vazalore [OTC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F55707797"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Entrophen;</li>
<li>Praxis ASA EC;</li>
<li>Rivasa;</li>
<li>Rivasa FC</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051174"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Analgesic, Nonopioid</span>;</li>
<li>
<span class="list-set-name">Anti-inflammatory Agent</span>;</li>
<li>
<span class="list-set-name">Antiplatelet Agent</span>;</li>
<li>
<span class="list-set-name">Antipyretic</span>;</li>
<li>
<span class="list-set-name">Nonsteroidal Anti-inflammatory Drug (NSAID), Oral</span>;</li>
<li>
<span class="list-set-name">Salicylate</span></li></ul></div>
<div class="block don drugH1Div" id="F53462377"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Do</b>
<b>sing: </b>Two immediate-release formulations are available: tablets and liquid-filled capsules (Vazalore). Immediate-release capsules cannot be divided and are not an appropriate dosage form for neonatal patients. All pediatric dosing for immediate-release formulations unless otherwise specified. Doses are typically rounded to a convenient amount (eg, <sup>1</sup>/<sub>4</sub> of 81 mg tablet).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4219cbd5-0ed7-441e-8688-c5772a0f8aa0">Antiplatelet effects; postoperative congenital heart repair or recurrent arterial ischemic stroke</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiplatelet effects; postoperative </b>
<b>congenital heart repair or recurrent arterial ischemic stroke: </b>Limited data available: Full-term neonate: Oral: Adequate neonatal studies have not been performed; neonatal dosage is derived from clinical experience and is not well established; suggested doses: 1 to 5 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>). Doses are typically rounded to a convenient amount (eg, <sup>1</sup>/<sub>4</sub> of 81 mg tablet)</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F137119"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Two immediate-release formulations are available: tablets and liquid-filled capsules (Vazalore). Immediate-release capsules cannot be divided and may not be an appropriate dosage form for some pediatric patients. All pediatric dosing for immediate-release formulations unless otherwise specified. Doses are typically rounded to a convenient amount (eg, <sup>1</sup>/<sub>4</sub> of 81 mg tablet).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c6ec689-e9af-41ae-8ca3-0221147a37b3">Analgesic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Analgesic:</b> Oral, rectal: <b>Note:</b> Do not use aspirin in pediatric patients &lt;18 years who have or who are recovering from chickenpox or flu symptoms (eg, viral illness) due to the association with Reye syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents weighing &lt;50 kg: Limited data available: 10 to 15 mg/kg/dose every 4 to 6 hours; maximum daily dose: 90 mg/kg/<b>day</b> or 4,000 mg/<b>day</b> whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents weighing ≥50 kg: 325 to 650 mg every 4 to 6 hours; maximum daily dose: 4,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="462a3a59-e36e-4308-9661-36c83a515c19">Anti-inflammatory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory:</b> Limited data available: Infants, Children, and Adolescents: Oral: Initial: 60 to 90 mg/kg/<b>day</b> in divided doses; usual maintenance: 80 to 100 mg/kg/<b>day</b> divided every 6 to 8 hours; monitor serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-724339','lexi-content-ref-1379157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-724339','lexi-content-ref-1379157'])">Ref</a></span>).<b> Note:</b> Although included in some product labeling, the use of salicylates including aspirin for the treatment of juvenile idiopathic arthritis has been replaced by other pharmacologic agents with improved efficacy and adverse effect profiles (eg, nonsalicylate nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, glucocorticoids, biologic modifiers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31021516','lexi-content-ref-24339215','lexi-content-ref-27747582','lexi-content-ref-29357887']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31021516','lexi-content-ref-24339215','lexi-content-ref-27747582','lexi-content-ref-29357887'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="72305440-84cf-444d-bd2e-a15f1970317b">Antiplatelet effect</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiplatelet effect:</b> Limited data available: Infants, Children, and Adolescents: Oral: Adequate pediatric studies have not been performed; pediatric dosage is derived from adult studies. Usual adult maximum daily dose for antiplatelet effects is 325 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute ischemic stroke (AIS):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Noncardioembolic: 1 to 5 mg/kg/dose once daily for ≥2 years; patients with recurrent AIS or TIAs should be transitioned to clopidogrel, LMWH, or warfarin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Secondary to Moyamoya and non-Moyamoya vasculopathy: 1 to 5 mg/kg/dose once daily; <b>Note:</b> In non-Moyamoya vasculopathy, continue aspirin for 3 months, with subsequent use guided by repeat cerebrovascular imaging (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prosthetic heart valve: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Bioprosthetic aortic valve (with normal sinus rhythm): 1 to 5 mg/kg/dose once daily for 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315257','lexi-content-ref-22315277','lexi-content-ref-24226806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315257','lexi-content-ref-22315277','lexi-content-ref-24226806'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Mechanical aortic and/or mitral valve: 1 to 5 mg/kg/dose once daily combined with vitamin K antagonist (eg, warfarin) is recommended as first-line antithrombotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315257','lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315257','lexi-content-ref-22315277'])">Ref</a></span>). Alternative regimens: 6 to 20 mg/kg/dose once daily in combination with dipyridamole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4036839','lexi-content-ref-3796033','lexi-content-ref-8481259','lexi-content-ref-3654744','lexi-content-ref-1990763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4036839','lexi-content-ref-3796033','lexi-content-ref-8481259','lexi-content-ref-3654744','lexi-content-ref-1990763'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Shunts: Blalock-Taussig; Glenn; postoperative; primary prophylaxis:</i> 1 to 5 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-24226806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-24226806'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Norwood, Fontan surgery, postoperative; primary prophylaxis:</i> 1 to 5 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-24226806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-24226806'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Transcatheter Atrial Septal Defect (ASD) or Ventricular Septal Defect (VSD) devices, postprocedure prophylaxis:</i> 1 to 5 mg/kg/dose once daily starting one to several days prior to implantation and continued for at least 6 months. For older children and adolescents, after device closure of ASD, an additional anticoagulant may be given with aspirin for 3 to 6 months, but the aspirin should continue for at least 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24226806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24226806'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ventricular assist device (VAD) placement:</i> 1 to 5 mg/kg/dose once daily initiated within 72 hours of VAD placement; should be used with heparin (initiated between 8 to 48 hours following implantation) and with or without dipyridamole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3323746a-ced0-47b1-98d4-d1c674bf951f">Kawasaki disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kawasaki disease, treatment:</b> Limited data available: <b>Note:</b> Patients with Kawasaki disease and presenting with influenza or viral illness should not receive aspirin; acetaminophen is suggested as an alternate antipyretic in these patients and an alternate antiplatelet agent is suggested for a minimum of 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28356445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28356445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Initial therapy (acute phase): <b>Note: </b>Optimal dose not established. Use in combination with IV immune globulin.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Moderate dose:</i> Oral: 30 to 50 mg/kg/<b>day</b> divided every 6 hours until fever resolves for at least 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28356445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28356445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>High dose</i>: Oral: 80 to 100 mg/kg/<b>day</b> divided every 6 hours until fever resolves for at least 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-24226806','lexi-content-ref-28356445','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-24226806','lexi-content-ref-28356445','lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Subsequent therapy (low-dose; antiplatelet effects): Infants and Children: Oral: 3 to 5 mg/kg/<b>day</b> once daily; initiate at least 48 to 72 hours after resolution of fever and continue for 6 to 8 weeks in patients without coronary artery abnormalities. In patients with coronary artery abnormalities ranging from dilation to large/giant aneurysms, low-dose aspirin should be continued (with or without dual antiplatelet therapy, warfarin or low molecular weight heparin); duration of aspirin therapy is based upon severity of coronary artery involvement; recommend consulting published treatment and institutional guidelines, and expert medical consultation for additional guidance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35257507','lexi-content-ref-24226806','lexi-content-ref-28356445','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35257507','lexi-content-ref-24226806','lexi-content-ref-28356445','lexi-content-ref-AAP.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2409ba83-3fab-48ac-bd75-41b00b70b569">Multisystem inflammatory syndrome in children associated with SARS-CoV-2</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 (antiplatelet/antithrombotic effects): </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Recommended for all MIS-C patients without active bleeding, significant bleeding risk, or platelet count ≤80,000 cells/mm<sup>3</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35118829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35118829'])">Ref</a></span>). Use is based on limited experience in patients with MIS-C, emerging data in adults with COVID-19, and extrapolation from Kawasaki disease and myocarditis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35118829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35118829'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 3 to 5 mg/kg/<b>day</b> once daily; maximum daily dose: 81 mg/<b>day</b>; continue until normalization of platelet count, confirmed normal coronary arteries at ≥4 weeks after diagnosis, and ejection fraction &gt;35% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35118829','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35118829','lexi-content-ref-NIH.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a5c2691-384d-40d4-87d0-48f2fec6a018">Rheumatic fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatic fever:</b> Limited data available: Infants, Children, and Adolescents: Oral: Initial: 100 mg/kg/<b>day</b> divided into 4 to 5 doses; if response inadequate, may increase dose to 125 mg/kg/<b>day</b>; continue for 2 weeks; then decrease dose to 60 to 70 mg/kg/<b>day</b> in divided doses for an additional 3 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Migratory polyarthritis, with carditis without cardiomegaly or congestive heart failure:</i> Oral: Initial: 50 to 70 mg/kg/<b>day</b> in 4 divided doses for 3 to 5 days, followed by 50 mg/kg/<b>day</b> in 4 divided doses for 2 to 3 weeks, followed by 25 mg/kg/<b>day</b> in 4 divided doses for 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>); escalation to doses up to 80 to 100 mg/kg/<b>day </b>in 4 or 5 divided doses has been described for arthritis management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-RHDAustralia.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-RHDAustralia.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Carditis and more than minimal cardiomegaly or congestive heart failure:</i>
<b>Note: </b>Aspirin should be initiated at the beginning of prednisone taper regimen to prevent rebound inflammation: Oral: 50 mg/kg/<b>day</b> in 4 divided doses for 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51065050"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: There are no recommendations in the manufacturer's labeling; however, the following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">GFR ≥10 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent hemodialysis: Dialyzable: 50% to 100% (concentration dependent; higher salicylate concentrations are more readily dialyzable) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25986310','lexi-content-ref-7016383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25986310','lexi-content-ref-7016383'])">Ref</a></span>); administer daily dose after dialysis session on dialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: Avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">CRRT: No dosage adjustment necessary; monitor serum concentrations.</p></div>
<div class="block dohp drugH1Div" id="F51065051"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All ages: Avoid use in severe liver disease.</p></div>
<div class="block doa drugH1Div" id="F137098"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8907" href="/d/html/8907.html" rel="external">see "Aspirin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Avoid regular or frequent use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients taking aspirin for cardiovascular protection as these may reduce the cardioprotective effects of aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15837265','lexi-content-ref-11752357','lexi-content-ref-12598144']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15837265','lexi-content-ref-11752357','lexi-content-ref-12598144'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing information below is based on the IR formulations; do not use the ER formulation in situations when a rapid onset of action is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> In patients who require concomitant therapeutic anticoagulation, antiplatelet selection and/or duration of therapy may differ in order to balance risks for thrombosis and bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33250267']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33250267'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9711994a-0550-4a1a-aeb1-10d6b3a50595">Analgesic/Antipyretic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Analgesic/Antipyretic: Immediate release: Oral:</b> 325 mg to 1 g every 4 to 6 hours as needed; usual maximum daily dose: 4 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Abramson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Abramson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> If patient cannot take orally, rectal suppositories (300 or 600 mg) are available.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fdd42ea4-4039-4053-80be-3a89d15becfb">Anti-inflammatory for arthritis associated with rheumatic disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory for arthritis associated with rheumatic disease: Immediate release: Oral:</b> 4 to 8 g/day in 4 to 5 divided doses as needed; titrate dose based on response and tolerability. Continue treatment until symptoms resolve (typically 1 to 2 weeks, but potentially up to 8 weeks). Use of aspirin at these high doses (4 to 8 g/day) may be limited by adverse effects (tinnitus, diminished auditory acuity, GI intolerance), making other available NSAIDs preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Abramson.1','lexi-content-ref-Carapetis.1','lexi-content-ref-Steer.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Abramson.1','lexi-content-ref-Carapetis.1','lexi-content-ref-Steer.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="15a3453f-4491-4f62-bddc-39b6311070ab">Atherosclerotic cardiovascular disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atherosclerotic cardiovascular disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute coronary syndrome: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For rapid onset, non–enteric-coated IR tablet(s) should be chewed and swallowed upon identification of clinical and ECG findings suggesting an acute coronary syndrome. Enteric-coated aspirin is not preferred, since onset of action may be delayed. If it is the only product available, enteric-coated IR tablet(s) may be chewed and swallowed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315278','lexi-content-ref-21544823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315278','lexi-content-ref-21544823'])">Ref</a></span>). For maintenance therapy, any oral formulation is acceptable for use.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Non–ST-elevation acute coronary syndromes or ST-elevation myocardial infarction: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>For initial therapy, administer aspirin in combination with an IV anticoagulant and a P2Y<sub>12</sub> inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Immediate release (non–enteric-coated): Oral:</b> 162 to 325 mg administered once (chew and swallow) at the time of diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Rectal (alternative route):</b> 600 mg administered once at the time of diagnosis if an IR oral formulation is unavailable or oral route is not feasible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19076101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19076101'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance (secondary prevention): </i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Immediate release: Oral:</b> 75 to 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-11520521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-11520521'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Duration of therapy: </i></p>
<p style="text-indent:-2em;margin-left:10em;">Preferred approach: Aspirin plus a P2Y<sub>12</sub> inhibitor (dual antiplatelet therapy [DAPT]) should be continued for ≥12 months, unless major bleeding is a concern. For patients at high risk of bleeding or who experience overt bleeding, DAPT for 6 months may be reasonable. If there have been no major bleeding complications after 12 months, continuation of DAPT may be considered. Reevaluate the need for DAPT at regular intervals based on bleeding and thrombotic risks. When DAPT is complete, discontinue the P2Y<sub>12</sub> inhibitor and continue aspirin indefinitely for secondary prevention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-25773268','lexi-content-ref-25399658','lexi-content-ref-11520521','lexi-content-ref-19717846','lexi-content-ref-17982182','lexi-content-ref-11519503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-25773268','lexi-content-ref-25399658','lexi-content-ref-11520521','lexi-content-ref-19717846','lexi-content-ref-17982182','lexi-content-ref-11519503'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Alternative approach in select patients to minimize bleeding events: Aspirin in combination with a P2Y<sub>12</sub> inhibitor (DAPT) should be continued for 1 to 3 months after PCI, then discontinue aspirin and continue P2Y<sub>12</sub> inhibitor monotherapy. When the P2Y<sub>12</sub> inhibitor is discontinued, restart aspirin for secondary prevention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-31237645','lexi-content-ref-32543684','lexi-content-ref-31556978','lexi-content-ref-32551860','lexi-content-ref-30166073','lexi-content-ref-31237644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-31237645','lexi-content-ref-32543684','lexi-content-ref-31556978','lexi-content-ref-32551860','lexi-content-ref-30166073','lexi-content-ref-31237644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Percutaneous coronary intervention for stable ischemic heart disease (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> For initial therapy, non–enteric-coated IR tablet(s) should be administered. Enteric-coated aspirin is not preferred since onset of action is delayed. For patients who receive a coronary stent during percutaneous coronary intervention, administer aspirin in combination with a parenteral anticoagulant and a P2Y<sub>12</sub> inhibitor (clopidogrel or ticagrelor; prasugrel is <b>not</b> recommended in this patient population) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Immediate</b>
<b> release (non–enteric-coated): Oral:</b> 162 to 325 mg given ≥2 hours (preferably 24 hours) before the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Immediate release: Oral:</b> 75 to 100 mg once daily in combination with clopidogrel <b>or</b> ticagrelor (DAPT) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>). Refer to clopidogrel or ticagrelor monograph for information on duration of DAPT and subsequent management.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Atherosclerotic cardiovascular disease, primary prevention (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Use should be a shared decision between health care professionals and patients ≥40 years of age who are at increased risk for cardiovascular disease, after weighing risks versus benefits. Some experts recommend against this use for patients ≥60 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35471505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35471505'])">Ref</a></span>), while others recommend against this use for patients &gt;70 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30879355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30879355'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immediate release: Oral:</b> 75 to 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30879355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30879355'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Atherosclerotic cardiovascular disease, secondary prevention:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Carotid </b>
<b>artery atherosclerosis, asymptomatic or symptomatic (off-label use):</b>
<b>Immediate release: Oral:</b> 75 to 325 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315275','lexi-content-ref-7723155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315275','lexi-content-ref-7723155'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Coronary artery bypass graft surgery:</b>
<b>Immediate release: Oral:</b> 75 to 81 mg once daily beginning preoperatively; continue indefinitely following surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25679302','lexi-content-ref-Aranki.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25679302','lexi-content-ref-Aranki.1'])">Ref</a></span>). Following surgery, some experts restart aspirin (with or without a one-time, 325 mg loading dose) approximately 6 hours after completion of the procedure or after extubation, whichever comes first (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aranki.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aranki.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>
<b>Off-pump coronary artery bypass graft surgery:</b></i>Following surgery, consider adding clopidogrel in combination with aspirin for 12 months then discontinue clopidogrel and continue aspirin indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25679302']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25679302'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Patients with acute coronary syndrome followed by coronary artery bypass graft surgery:</i></b> Administer aspirin in combination with a P2Y<sub>12</sub> inhibitor for 12 months then continue aspirin indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25679302']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25679302'])">Ref</a></span>). Some experts do not use P2Y<sub>12</sub> inhibitors postoperatively in these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aranki.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aranki.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Ischemic stroke/transient ischemic attack:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>In patients who receive IV thrombolytic therapy, antiplatelet therapy is generally delayed for at least 24 hours, but administered as soon as possible thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31662037','lexi-content-ref-Filho.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31662037','lexi-content-ref-Filho.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Due to intracranial large artery atherosclerosis (50% to 99%), secondary prevention:</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Avoid dual antiplatelet therapy (DAPT) in patients with hemorrhagic transformation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Filho.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Filho.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Immediate release: Oral:</b></p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Monotherapy:</i> 325 mg once daily. May consider a short course of DAPT as outlined below. (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34024117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34024117'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Short-term (90 days) DAPT with concomitant clopidogrel in patients with recent (≤30 days) stroke or TIA due to 70% to 99% stenosis of an intracranial large artery:</i> 325 mg once daily followed by long-term aspirin monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34024117','lexi-content-ref-Turan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34024117','lexi-content-ref-Turan.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Short-term (21 days) DAPT with concomitant clopidogrel in patients with recent (≤30 days) minor stroke or high-risk TIA due to 50% to 69% stenosis of an intracranial large artery</i>: 160 to 325 mg loading dose followed by 50 to 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Turan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Turan.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Short-term (21 to 30 days) DAPT with concomitant ticagrelor in patients with recent (≤24 hours) minor stroke or high-risk TIA and &gt;30% stenosis of ipsilateral major intracranial artery:</i> 300 to 325 mg loading dose followed by 75 to 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34024117','lexi-content-ref-Filho.1','lexi-content-ref-Brilinta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34024117','lexi-content-ref-Filho.1','lexi-content-ref-Brilinta.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Due to other noncardioembolic causes (eg, small vessel disease), secondary prevention:</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For patients with recent (eg, ≤24 hours) minor stroke or high-risk TIA, may consider short-term DAPT with concomitant clopidogrel (21 to 90 days) or ticagrelor (21 to 30 days) followed by long-term single-agent antiplatelet therapy with aspirin, clopidogrel, or aspirin/ER dipyridamole. Avoid DAPT in patients with hemorrhagic transformation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34024117','lexi-content-ref-Filho.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34024117','lexi-content-ref-Filho.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Initial: </i></p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Immediate release: Oral:</b> 160 to 325 mg administered once at the time of diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31662037','lexi-content-ref-Filho.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31662037','lexi-content-ref-Filho.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Rectal (alternative route):</b> 300 mg administered once at the time of diagnosis if oral route is not feasible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31662037','lexi-content-ref-9174558','lexi-content-ref-24668137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31662037','lexi-content-ref-9174558','lexi-content-ref-24668137'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Maintenance</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Immediate release: Oral:</b> 50 to 325 mg once daily; some experts recommend 50 to 100 mg once daily when used with clopidogrel for DAPT and as long-term single-agent therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315273','lexi-content-ref-34024117','lexi-content-ref-Cucchiara.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315273','lexi-content-ref-34024117','lexi-content-ref-Cucchiara.1'])">Ref</a></span>). When used with ticagrelor for DAPT, 75 to 100 mg once daily is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brilinta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brilinta.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Peripheral atherosclerotic disease (upper or lower extremity; with or without a revascularization procedure) (off-label use):</b>
<b>Immediate release: Oral:</b> 75 to 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315275','lexi-content-ref-27840333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315275','lexi-content-ref-27840333'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Stable ischemic heart disease: Immediate release: Oral:</b> 75 to 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211','lexi-content-ref-Kannam.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211','lexi-content-ref-Kannam.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f4279d92-24ed-42de-bfa6-a1d30d71a104">Carotid artery stenting</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Carotid artery stenting (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Percutaneous approach:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Initiation ≥48 hours before procedure</i>: Immediate release: Oral:</b> 325 mg twice daily in combination with clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20505173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20505173'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Initiation &lt;48 hours before procedure</i>: Immediate release: Oral:</b> 650 mg once at least 4 hours before procedure in combination with clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20505173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20505173'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Immediate release: Oral:</b> 75 to 325 mg once daily in combination with clopidogrel for at least 4 weeks, then discontinue clopidogrel and continue aspirin 75 to 325 mg once daily indefinitely thereafter. In patients with history of neck irradiation, some experts recommend continuing aspirin plus clopidogrel indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21282493','lexi-content-ref-20505173','lexi-content-ref-Jim.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21282493','lexi-content-ref-20505173','lexi-content-ref-Jim.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transcarotid approach:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>
<b>Initiation ≥72 hours before procedure:</b></i>
<b> Immediate release: Oral:</b> 75 to 325 mg once daily in combination with clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26506270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26506270'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>
<b>Initiation &lt;72 hours before procedure</b></i>
<b>: Immediate release: Oral:</b> 650 mg once at least 4 hours before procedure in combination with clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26506270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26506270'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Immediate release: Oral:</b> 75 to 325 mg once daily in combination with clopidogrel for at least 4 weeks, then discontinue clopidogrel and continue aspirin 75 to 325 mg once daily indefinitely thereafter. In patients with history of neck irradiation, some experts recommend continuing aspirin plus clopidogrel indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20505173','lexi-content-ref-Jim.2','lexi-content-ref-26506270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20505173','lexi-content-ref-Jim.2','lexi-content-ref-26506270'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf23572b-d820-42fc-93cf-3ed79fd17097">Carotid endarterectomy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Carotid endarterectomy:</b>
<b>Immediate release: Oral:</b> 75 to 325 mg once daily starting prior to surgery and continued indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315275','lexi-content-ref-Fairman.2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315275','lexi-content-ref-Fairman.2019b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e4558210-97c4-494b-93ef-8d7a1a676817">Colorectal cancer risk reduction, primary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer risk reduction, primary prevention (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The optimal dose and duration of therapy for colorectal cancer risk reduction are unknown. Utilization should be a shared decision between health care professionals and patients that weighs the risk versus benefits of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chan.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> 75 to 325 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chan.1','lexi-content-ref-20970847','lexi-content-ref-23451245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chan.1','lexi-content-ref-20970847','lexi-content-ref-23451245'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94e2a3ee-a6a7-47a4-9a9e-1102ebb9cf5e">Migraine, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, acute treatment (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For mild to moderate attacks not associated with vomiting or severe nausea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schwedt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schwedt.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> 900 mg or 1 g once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15836564','lexi-content-ref-12010380']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15836564','lexi-content-ref-12010380'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="236d546c-b735-4016-861b-18e58e48239e">Pericarditis, acute or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pericarditis, acute or recurrent (off-label use):</b></p>
<p style="text-indent:0em;margin-left:4em;">
<b>Note: </b>Aspirin is preferred over other nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with ischemic heart disease. If pericarditis occurs secondary to acute myocardial infarction (MI), avoid NSAIDs (other than once-daily, low-dose aspirin for treatment of MI) and use acetaminophen for analgesia. If this does not suffice or if additional pericarditis treatment is necessary after 7 to 10 days, aspirin is preferred and other NSAIDs should continue to be avoided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-LeWinter.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-LeWinter.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> Initial: 650 mg to 1 g every 8 hours until resolution of symptoms for at least 24 hours and normalization of inflammatory biomarkers (eg, C-reactive protein) if monitored; initial therapy typically lasts for ≥1 to 2 weeks. Gradually taper over several weeks by decreasing each dose by 250 to 500 mg every 1 to 2 weeks; during taper, ensure patient remains asymptomatic and inflammatory biomarkers remain normal (if monitored). Use in combination with colchicine. In patients at risk of NSAID-related GI toxicity, prophylaxis (generally with a proton pump inhibitor) is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26320112','lexi-content-ref-Imazio.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26320112','lexi-content-ref-Imazio.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fceb35e6-be75-43a9-87ea-ddf393abe4b9">Polycythemia vera, prevention of thrombosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Polycythemia vera, prevention of thrombosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Avoid use in patients with concurrent acquired von Willebrand syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tefferi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tefferi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> 75 to 100 mg once or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16781485','lexi-content-ref-30478826','lexi-content-ref-14711910','lexi-content-ref-22234683','lexi-content-ref-27991718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16781485','lexi-content-ref-30478826','lexi-content-ref-14711910','lexi-content-ref-22234683','lexi-content-ref-27991718'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8133abed-4566-47f7-ae80-280fc4e24e95">Preeclampsia prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Preeclampsia prevention (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use in pregnant women with ≥2 moderate risk factors or ≥1 high risk factor for preeclampsia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29939940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29939940'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> 81 to 162 mg once daily, ideally beginning between 12 to 16 weeks' gestation but may be started up to 28 weeks' gestation; continue therapy until delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29939940','lexi-content-ref-28657417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29939940','lexi-content-ref-28657417'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1877efa8-0481-41bf-aab5-ffa70a45997d">Valvular heart disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Valvular heart disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Surgical prosthetic heart valve replacement, thromboprophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Bioprosthetic aortic or mitral heart valve replacement (off-label use): Note:</b> Timing of aspirin initiation is based on bleeding risk. For patients at low risk of bleeding, treat with warfarin monotherapy for 3 to 6 months, then transition to aspirin monotherapy. For patients at elevated risk of bleeding, initiate aspirin within 24 hours of surgery (ie, no initial treatment with warfarin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33332150','lexi-content-ref-Konkle.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33332150','lexi-content-ref-Konkle.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Immediate release: Oral:</b> 75 to 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33332150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33332150'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Mechanical aortic or mitral heart valve replacement (off-label use): Note:</b> Aspirin is required, in combination with warfarin, for patients who receive an On-X mechanical aortic valve. For other mechanical valve types, consider risks of thromboembolism and bleeding before adding aspirin; warfarin monotherapy is typically sufficient. Addition of aspirin is not routinely required in the absence of another indication for antiplatelet therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33332150','lexi-content-ref-24512654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33332150','lexi-content-ref-24512654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Immediate release: Oral:</b> 75 to 100 mg once daily in combination with warfarin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33332150','lexi-content-ref-24512654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33332150','lexi-content-ref-24512654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transcatheter <i>aortic</i> valve replacement, thromboprophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Refer to institutional policies and procedures on use of antiplatelet therapy for patients who require therapeutic anticoagulation for a different indication.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immediate release: Oral:</b> 75 to 100 mg once daily; may use in combination with clopidogrel for 3 to 6 months after transcatheter aortic valve replacement, depending on type of valve implanted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33332150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33332150'])">Ref</a></span>). To minimize risk of bleeding complications, may give aspirin <b>or</b> clopidogrel alone and reserve dual antiplatelet therapy during the first 3 to 6 months for patients at high risk of a thrombotic event; for either strategy, continue aspirin indefinitely after the initial 3 to 6 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32865376','lexi-content-ref-31609071']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32865376','lexi-content-ref-31609071'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transcatheter <i>mitral</i> valve repair with MitraClip device, thromboprophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patients are generally treated with antithrombotic therapy (antiplatelet or anticoagulant if there is a concurrent indication) for at least 6 months following the procedure.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immediate release: Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Loading dose: </b>325 mg once immediately following MitraClip insertion or within 24 hours prior to the procedure; use in combination with clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30280640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30280640'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Maintenance: </b>81 mg once daily for at least 6 months; may use as monotherapy or in combination with clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30280640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30280640'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b25a3820-a99f-4b00-aeb9-b89121f5970b">Venous thromboembolism prevention, indefinite therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism prevention, indefinite therapy (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in select patients to prevent recurrent venous thromboembolism (VTE) if unable to take an anticoagulant. In patients who have completed ≥6 months of anticoagulation and in whom indefinite therapeutic anticoagulation is indicated, aspirin is not recommended since it is less effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> 100 mg once daily after completion of a conventional treatment course with therapeutic anticoagulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22621626','lexi-content-ref-23121403','lexi-content-ref-25156992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22621626','lexi-content-ref-23121403','lexi-content-ref-25156992'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da459878-e233-42b5-8919-c5cd252eda06">Venous thromboembolism prophylaxis for total hip or total knee arthroplasty</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism prophylaxis for total hip or total knee arthroplasty (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Some experts limit this strategy to lower-risk patients who undergo elective unilateral total hip arthroplasty (THA) or total knee arthroplasty (TKA), ambulate within 24 hours after surgery, and do not have additional risk factors for VTE, indications for long-term anticoagulation, lower limb or hip fracture in the previous 3 months, or expected major surgery in the upcoming 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pai.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pai.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> Begin postoperative prophylaxis with rivaroxaban or a low-molecular-weight heparin, then discontinue therapy after 5 days for TKA or after 5 to 10 days for THA, and initiate aspirin 81 mg once daily. For TKA, continue aspirin through postoperative day 10 to 14 (if not fully ambulatory by day 14, may continue through postoperative day 35). For THA, continue aspirin through postoperative day 35 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29466159','lexi-content-ref-23732713','lexi-content-ref-Pai.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29466159','lexi-content-ref-23732713','lexi-content-ref-Pai.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="50f22574-9abb-4a69-b984-cbeefe234395">Venous thromboembolism prophylaxis in lower-risk patients with multiple myeloma receiving immunomodulatory therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism prophylaxis in lower-risk patients with multiple myeloma receiving immunomodulatory therapy (eg, lenalidomide, pomalidomide, thalidomide) (off-label use): Oral: </b>81 to 100 mg once daily during immunomodulatory therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21835953','lexi-content-ref-21282540','lexi-content-ref-16118317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21835953','lexi-content-ref-21282540','lexi-content-ref-16118317'])">Ref</a></span>).<b></b></p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990662"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Antiplatelet uses:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In general the benefit of low-dose aspirin outweighs any risk associated with nephropathy or other adverse effects even in the setting of severe kidney impairment; the recommended aspirin dose should not be reduced in any patient with suspected or documented cardiovascular disease, or other antithrombotic indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11172556','lexi-content-ref-112475','lexi-content-ref-26528445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11172556','lexi-content-ref-112475','lexi-content-ref-26528445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11172556','lexi-content-ref-112475','lexi-content-ref-26528445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11172556','lexi-content-ref-112475','lexi-content-ref-26528445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Analgesia or anti-inflammatory uses:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;10 mL/minute: No dosage adjustment necessary; however, high doses have been associated with acute kidney injury (AKI) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19585463']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19585463'])">Ref</a></span>). Use lowest effective dosage and limit duration of therapy, particularly for patients at high risk for developing AKI (eg, patients with chronic kidney disease, volume depletion, older age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19585463','lexi-content-ref-28764659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19585463','lexi-content-ref-28764659'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: Avoid use (manufacturer's labeling; expert opinion). May exacerbate uremic GI and hematologic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Avoid use. May exacerbate uremic GI and hematologic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2868341','lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2868341','lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Avoid use. May exacerbate uremic GI and hematologic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987885"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Avoid use in severe liver disease.</p></div>
<div class="block arsc drugH1Div" id="F56328073"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Aspirin use is associated with a 2- to 4-fold increase in upper gastrointestinal (UGI) events, such as symptomatic or complicated <b>gastrointestinal ulcers</b> and GI mucosal damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29908361','lexi-content-ref-24741318','lexi-content-ref-31025592']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29908361','lexi-content-ref-24741318','lexi-content-ref-31025592'])">Ref</a></span>). Lower GI (LGI) events have also been reported with chronic aspirin use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29908361','lexi-content-ref-31025592']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29908361','lexi-content-ref-31025592'])">Ref</a></span>). Symptoms can range from mild (<b>dyspepsia</b>) to severe (peptic ulcer disease, <b>gastrointestinal hemorrhage</b>). The use of enteric-coated preparations of aspirin does not decrease the risk of UGI events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26369688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26369688'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action; damage to the GI mucosa is typically caused by aspirin's effects on the epithelial and microvascular tissue of the GI tract via inhibition of cyclooxygenase-1 and subsequent prostaglandin depletion, which is gastro-protective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24741318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24741318'])">Ref</a></span>). Additionally, aspirin accumulates in gastric mucosal cells, altering the permeability, resulting in an increased risk of ulceration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24741318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24741318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; topical gastric mucosa toxicity can be seen on endoscopy within minutes of aspirin administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24741318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24741318'])">Ref</a></span>). Other studies reported GI ulcers after at least 3 months of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24215903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24215903'])">Ref</a></span>). Risk of GI events is generally seen when beginning aspirin therapy; however, long-term administration of aspirin is associated with a greater risk of GI events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24741318','lexi-content-ref-24215903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24741318','lexi-content-ref-24215903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose &gt;100 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15877994']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15877994'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Bleeding ulcers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24741318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24741318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Peptic ulcer disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24741318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24741318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of nonsteroidal anti-inflammatory drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24741318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24741318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24741318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24741318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent dual antiplatelet and anticoagulant therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24741318','lexi-content-ref-20458022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24741318','lexi-content-ref-20458022'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• Helicobacter pylori</i> infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24741318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24741318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24741318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24741318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Excessive alcohol consumption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24741318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24741318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (&gt;70 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24741318','lexi-content-ref-26369688','lexi-content-ref-30221597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24741318','lexi-content-ref-26369688','lexi-content-ref-30221597'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions (immediate and delayed) involving the skin (eg, <b>angioedema</b>, <b>urticaria</b>), airways (eg, dyspnea, rhinorrhea), and/or other organs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>) have been reported. Clinical phenotypes of aspirin/nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity reactions include aspirin/NSAID-exacerbated respiratory disease (AERD and NERD), aspirin/NSAID-induced urticaria/angioedema (NIUA), aspirin/NSAID-exacerbated cutaneous disease (NICD) and single NSAID-induced urticaria/angioedema or <b>anaphylaxis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31545385','lexi-content-ref-24117484','lexi-content-ref-32957109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31545385','lexi-content-ref-24117484','lexi-content-ref-32957109'])">Ref</a></span>). Delayed hypersensitivity reactions, including <b>drug rash with eosinophilia and systemic symptoms </b>(DRESS), have also been rarely associated with aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19103366','lexi-content-ref-26928755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19103366','lexi-content-ref-26928755'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Immediate reactions: Non–dose-related; most reactions (ie, AERD, NERD, NECD, NIUA) are nonimmunologic related to inhibition of cyclooxygenase-1 (COX-1) with subsequent activation of mast cells and eosinophils causing release of inflammatory mediators including cysteinyl-leukotrienes (cysLTs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). Some immediate reactions are IgE-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31496752']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31496752'])">Ref</a></span>); although, these are rare with aspirin and more common with NSAIDs, where they can be associated with an immediate reaction specific to the specific NSAID or class of NSAID. Delayed hypersensitivity reactions, including DRESS, are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-25749768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-25749768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Immediate hypersensitivity reactions: Rapid; occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). Delayed hypersensitivity reactions, including DRESS: Varied, by definition occur after 6 hours of exposure but most commonly occur 2 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-19103366','lexi-content-ref-NICE.1','lexi-content-ref-26928755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-19103366','lexi-content-ref-NICE.1','lexi-content-ref-26928755'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of chronic rhinosinusitis with nasal polyps, family history of AERD/NERD, and/or severe asthma may increase the risk of AERD/NERD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30216468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30216468'])">Ref</a></span>). The prevalence of NERD in adult patients with asthma is ~10% to 20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30216468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30216468'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic urticaria increases the risk of NECD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). Aspirin-induced reactions are less frequent and less intense when chronic urticaria is in remission or under control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25749768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25749768'])">Ref</a></span>). Approximately 12% to 30% of patients with chronic idiopathic urticaria develop exacerbations of their disease with use of aspirin and other COX-1 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28483309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28483309'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between aspirin and NSAIDs (with predominant COX-1 inhibition) have been described in patients with a history of NERD, NECD, and NIUA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). Patients who develop a reaction (immediate or delayed) to only aspirin or a single NSAID are often able to tolerate chemically unrelated NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25749768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25749768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Pharmacological cross-reactivity between aspirin and acetaminophen, a weak COX-1 inhibitor, and between aspirin and nonselective COX-2 inhibitors (eg, meloxicam, nimesulide) may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21834936','lexi-content-ref-17609236','lexi-content-ref-32789114']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21834936','lexi-content-ref-17609236','lexi-content-ref-32789114'])">Ref</a></span>). Due to the weak COX-1 inhibitory activity, AERD reactions associated with acetaminophen typically only occur with higher doses such as &gt;4 g/day. Although selective COX-2 inhibitors (eg, celecoxib, etoricoxib) are generally tolerated in patients with AERD or NERD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21631520','lexi-content-ref-30207919']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21631520','lexi-content-ref-30207919'])">Ref</a></span>), pharmacological cross-reactions may occur, especially in patients with histories of urticaria/angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21834936','lexi-content-ref-24587953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21834936','lexi-content-ref-24587953'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Although earlier reports suggested that tartrazine and aspirin/NSAIDs may cross react, more recent clinical evidence has indicated that tartrazine is well-tolerated in patients with AERD/NERD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3722646','lexi-content-ref-12668895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3722646','lexi-content-ref-12668895'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Despite structural similarity between aspirin and 5-aminosalicylic acid (ASA) (mesalamine), there is lack of evidence demonstrating occurrence of AERD in association with 5-ASA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24634525']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24634525'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F137057"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As with all drugs which may affect hemostasis, bleeding is associated with aspirin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables including dosage, concurrent use of multiple agents which alter hemostasis, and patient susceptibility. Many adverse reactions with aspirin are dose related and are rare at low dosages. Other serious reactions are idiosyncratic, related to allergy or individual sensitivity. Accurate estimation of frequencies is not possible.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, hypotension, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, hyperglycemia, hyperkalemia, hypoglycemia (children), increased thirst, metabolic acidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, dyspepsia, gastrointestinal perforation, gastrointestinal ulcer, heartburn, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Postpartum hemorrhage, post-term pregnancy, prolonged labor, proteinuria, stillborn infant</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disorder of hemostatic components of blood, disseminated intravascular coagulation, hemorrhage, prolonged bleeding time, prolonged prothrombin time, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, brain edema, coma, confusion, dizziness, headache, hypothermia, lethargy, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine, interstitial nephritis, renal failure syndrome, renal insufficiency, renal papillary necrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hyperventilation, laryngeal edema, pulmonary edema, respiratory alkalosis, tachypnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, low birth weight</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (Kowalski 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperuricemia (doses ≤325 mg/day) (Caspi 2000; Segal 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage (Garcia Rodriguez 2019), pancreatitis (Hoyte 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Kowalski 2013), angioedema (Kowalski 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Kawakami 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Intracranial hemorrhage (Huang 2019), Reye's syndrome (McGovern 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis (Leventhal 1989)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Macular degeneration (age-related) (Li 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss (Koren 2009), tinnitus (Koren 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (Kowalski 2013), bronchospasm (Kowalski 2013)</p></div>
<div class="block coi drugH1Div" id="F137072"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to NSAIDs; patients with asthma, rhinitis, and nasal polyps; use in children or teenagers for viral infections, with or without fever.</p></div>
<div class="block war drugH1Div" id="F137054"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: ­</p>
<p style="text-indent:-2em;margin-left:6em;">– Altered absorption and efficacy: Altered absorption and efficacy may occur. The T<sub>max</sub> of salicylic acid after gastric bypass was observed to be significantly shorter after surgery. C<sub>max</sub> and AUC<sub>0-24</sub> were also significantly higher (Mitrov-Winkelmolen 2016). In a mixed surgery population (80% gastric bypass, 20% sleeve), aspirin-induced platelet reactivity was significantly reduced and correlated to the extent of weight loss after surgery (Norgard 2017). ­</p>
<p style="text-indent:-2em;margin-left:6em;">– Gastric ulceration: Evaluate the risk vs benefit of aspirin after surgery; if aspirin therapy is continued (eg, cardiovascular indications), use the lowest possible dose with concurrent administration of proton pump inhibitor (PPI); risk of gastric ulceration after gastric bypass and sleeve gastrectomy may be increased. A population-based study of over 20,000 patients identifying risk factors for marginal ulceration after gastric bypass suggests limited doses of aspirin may not increase risk whereas higher doses may (Sverden 2016). Another study identified that following gastric bypass, there is no significant difference in marginal ulceration rate between those given low-dose aspirin and those not on aspirin; however, long-term PPI therapy (&gt;90 days) was found to significantly reduce marginal ulceration rate in both groups (Kang 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with platelet and bleeding disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dehydration: Use with caution in patients with dehydration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ethanol use: Heavy ethanol use (&gt;3 drinks/day) can increase bleeding risks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Use with caution in patients with erosive gastritis. Avoid use in patients with active peptic ulcer disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Avoid use in severe hepatic failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use high dosages (eg, analgesic or anti-inflammatory uses) with caution (NKF [Henrich 1996]; Whelton 2000). Low-dose aspirin (eg, 75 to 162 mg daily) may be safely used in patients with any degree of renal impairment (KDOQI 2005; KDOQI 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombolytics: In the treatment of acute ischemic stroke, avoid aspirin for 24 hours following administration of a thrombolytic; administration within 24 hours increases the risk of hemorrhagic transformation (AHA/ASA [Powers 2019]; Jauch 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI bleed patients: An individualized and multidisciplinary approach should be used to manage patients with an acute GI bleed who are on antiplatelet medications. Aspirin for primary prevention of cardiovascular events should be avoided in most patients with GI bleed who do not have high risk factors for cardiovascular events. However, aspirin for secondary cardiovascular prevention should <i>not </i>be discontinued in patients with established cardiovascular disease, even in the setting of a GI bleed. If held in the setting of a GI bleed, aspirin for secondary cardiovascular prevention should be resumed on the day hemostasis is confirmed by endoscopy (ACG/CAG [Abraham 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: When used for self-medication (OTC labeling): Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use this product. Changes in behavior (along with nausea and vomiting) may be an early sign of Reye syndrome; patients should be instructed to contact their healthcare provider if these occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: Patients who have recently undergone percutaneous coronary intervention with stenting or balloon angioplasty should continue antiplatelet therapy until it is safe to temporarily hold treatment. In patients undergoing CABG, aspirin may be continued until the time of surgery. Elective surgery for these patients should be delayed. Aspirin can typically be continued perioperatively in patients who undergo elective non-cardiac surgery. If aspirin interruption is necessary, discontinue therapy ≤7 days before surgery, and resume as soon as possible (eg, ≤24 hours) after surgery based on bleeding and thrombotic risks. Patient-specific situations should be discussed with cardiologist (ACC/AHA [Fleisher 2014]; ACC/AHA [Lawton 2022]; ACCP [Douketis 2022]; AHA/ACC/SCAI/ACS/ADA [Grines 2007]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Resistance: Aspirin resistance is defined as measurable, persistent platelet activation that occurs in patients prescribed a therapeutic dose of aspirin. Clinical aspirin resistance, the recurrence of some vascular event despite a regular therapeutic dose of aspirin, is considered aspirin treatment failure. Proposed mechanisms of aspirin resistance include poor adherence with therapy, poor absorption, inadequate dosage, drug interactions, increased isoprostane activity, platelet hypersensitivity to agonists, increased COX-2 activity, COX-1 polymorphism, and platelet alloantigen 2 polymorphism of platelet glycoprotein IIIa. Estimates of biochemical aspirin resistance range from 5.5% to 60% depending on the population studied and the assays used (Gasparyan 2008). Patients with aspirin resistance may have a higher risk of cardiovascular events compared to those who are aspirin sensitive (Gum 2003). Aspirin resistance is likely dose-related but may be influenced by dynamic factors yet to be identified; further research is required.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878339"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Do not use aspirin in pediatric patients &lt;18 years of age (APS 2016) who have or who are recovering from chickenpox or flu symptoms (due to the association with Reye syndrome); when using aspirin, changes in behavior (along with nausea and vomiting) may be an early sign of Reye syndrome; instruct patients and caregivers to contact their health care provider if these symptoms occur; patients should be kept current on their influenza and varicella immunizations. Although Reye syndrome has been observed in patients receiving prolonged, high-dose aspirin therapy after Kawasaki disease presentation; it has not been observed in pediatric patients receiving low (antiplatelet) dosing regimens. Patients with Kawasaki disease and presenting with influenza or viral illness should not receive aspirin; acetaminophen is suggested as an antipyretic in these patients, and an alternate antiplatelet agent is suggested for a minimum of 2 weeks (AHA [McCrindle 2017]).</p></div>
<div class="block foc drugH1Div" id="F137065"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Caplet, oral: 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Bayer Aspirin Extra Strength: 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Bayer Genuine Aspirin: 325 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Bayer Women's Low Dose Aspirin: 81 mg [contains elemental calcium 300 mg]</p>
<p style="text-indent:-2em;margin-left:2em;">Caplet, oral [buffered]:</p>
<p style="text-indent:-2em;margin-left:4em;">Bayer Plus Extra Strength: 500 mg [contains calcium carbonate]</p>
<p style="text-indent:-2em;margin-left:2em;">Caplet, enteric coated, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Bayer Aspirin Regimen Regular Strength: 325 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule Extended Release, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Durlaza: 162.5 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Vazalore: 81 mg, 325 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Suppository, rectal: 300 mg (12s); 600 mg (12s [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, oral: 325 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Aspercin: 325 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Aspirtab: 325 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Bayer Genuine Aspirin: 325 mg</p>
<p style="text-indent:-2em;margin-left:4em;">FT Aspirin: 325 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, oral [buffered]: 325 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Ascriptin Regular Strength: 325 mg [contains aluminum hydroxide, calcium carbonate, magnesium hydroxide]</p>
<p style="text-indent:-2em;margin-left:4em;">Buffasal: 325 mg [contains magnesium oxide]</p>
<p style="text-indent:-2em;margin-left:4em;">Bufferin: 325 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]</p>
<p style="text-indent:-2em;margin-left:4em;">Bufferin Extra Strength: 500 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]</p>
<p style="text-indent:-2em;margin-left:4em;">Buffinol: 324 mg [sugar free; contains magnesium oxide]</p>
<p style="text-indent:-2em;margin-left:4em;">Tri-Buffered Aspirin: 325 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, chewable, oral: 81 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Bayer Aspirin Regimen Children's: 81 mg [cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;">Bayer Aspirin Regimen Children's: 81 mg [orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;">St Joseph Adult Aspirin: 81 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, delayed release, oral: 81 mg, 325 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Aspirin Adult Low Dose: 81 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Aspirin Adult Low Strength: 81 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Aspirin EC Low Strength: 81 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Bayer Aspirin: 325 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">Bayer Aspirin EC Low Dose: 81 mg</p>
<p style="text-indent:-2em;margin-left:4em;">GoodSense Low Dose: 81 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, enteric coated, oral: 81 mg, 325 mg, 650 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Aspir-low: 81 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">Bayer Aspirin Regimen Adult Low Strength: 81 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Ecotrin: 325 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Halfprin: 81 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">St Joseph Adult Aspirin: 81 mg</p></div>
<div class="block geq drugH1Div" id="F137050"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F137074"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Vazalore Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">81 mg (per each): $0.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">325 mg (per each): $0.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Aspirin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">81 mg (per each): $0.02 - $0.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (St Joseph Low Dose Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">81 mg (per each): $0.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suppository</b> (Aspirin Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $1.46</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Aspirin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">81 mg (per each): $0.01 - $0.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">325 mg (per each): $0.02 - $0.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Bayer Aspirin EC Low Dose Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">81 mg (per each): $0.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Bayer Aspirin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">325 mg (per each): $0.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ascriptin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">325 mg (per each): $0.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Aspirin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">325 mg (per each): $0.01 - $0.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Bayer Aspirin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">325 mg (per each): $0.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Bufferin Extra Strength Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Bufferin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">325 mg (per each): $0.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Medi-First Aspirin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">325 mg (per each): $0.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Medique Aspirin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">325 mg (per each): $0.04</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55184557"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Rivasa FC: 80 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: 325 mg (24s, 50s, 100s, 120s, 200s, 500s), 500 mg (50s, 60s, 100s, 120s, 500s)</p>
<p style="text-indent:-2em;margin-left:2em;margin-right:0em;">Tablet Chewable, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Entrophen: 81 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Rivasa: 80 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet Delayed Release, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Entrophen: 81 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Praxis ASA EC: 81 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Rivasa: 80 mg, 81 mg</p></div>
<div class="block admp drugH1Div" id="F52612268"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with water, food, or milk to decrease GI upset.</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">Capsule: Swallow whole; do not cut, crush, or chew. Administer with a full glass of water.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablets: Do not crush or chew enteric-coated tablets; these preparations should be swallowed whole. In situations for which rapid onset of action is required, patient should chew immediate-release tablet.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Do not cut, crush, or chew. Administer with a full glass of water at the same time each day.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Remove suppository from plastic packet and insert into rectum as far as possible.</p></div>
<div class="block adm drugH1Div" id="F137069"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IR tablets: Administer with food or a full glass of water to minimize GI distress. In situations for which a rapid onset of action is required (eg, acute treatment of myocardial infarction), have patient chew IR tablet.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Preeclampsia (prevention):</i> Administration as an evening dose may be more beneficial than administration in the morning (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23004922','lexi-content-ref-28657417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23004922','lexi-content-ref-28657417'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">ER capsules: Do not cut, crush, or chew. Administer with a full glass of water at the same time each day. Do not administer 2 hours before or 1 hour after alcohol consumption.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal:</b> Remove suppository from plastic packet and insert into rectum as far as possible.</p></div>
<div class="block sts drugH1Div" id="F137087"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store oral dosage forms (caplets, tablets, capsules) at room temperature; protect from moisture; see product-specific labeling for details. Keep suppositories in refrigerator; do not freeze. Hydrolysis of aspirin occurs upon exposure to water or moist air, resulting in salicylate and acetate, which possess a vinegar-like odor. Do not use if a strong odor is present.</p></div>
<div class="block usep drugH1Div" id="F53565531"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: For the temporary relief of headache, pain, and fever caused by colds, muscle aches and pains, menstrual pain, toothache pain, and minor aches and pains of arthritis; to reduce the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli; to reduce the risk of vascular mortality in patients with a suspected acute MI, to reduce the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris; to reduce the combined risk of MI and sudden death in patients with chronic stable angina pectoris; adjunctive therapy in revascularization procedures (ie, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, carotid endarterectomy) (OTC: All products: FDA approved in adults; refer to product-specific labeling regarding FDA approval in pediatric patients, most products FDA approved in ages ≥12 years). Has also been used for rheumatic fever and antiplatelet effects for adjunctive treatment of Kawasaki disease and multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Reduce the risk of death and MI in patients with chronic coronary artery disease (eg, history of MI, unstable angina, or chronic stable angina); reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack (TIA) (All indications: FDA approved in adults). <b>Note</b>: Do not use extended-release capsules in situations for which a rapid onset of action is required (such as acute treatment of MI or before percutaneous coronary intervention); use immediate-release formulations instead.</p></div>
<div class="block mst drugH1Div" id="F137154"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Aspirin may be confused with Afrin</p>
<p style="text-indent:-2em;margin-left:4em;">Ascriptin may be confused with Aricept</p>
<p style="text-indent:-2em;margin-left:4em;">Ecotrin may be confused with Edecrin, Epogen</p>
<p style="text-indent:-2em;margin-left:4em;">Halfprin may be confused with Haltran</p>
<p style="text-indent:-2em;margin-left:4em;">ZORprin may be confused with Zyloprim</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">Anacin 81 [Puerto Rico] may be confused with Anacin brand name for lidocaine/prilocaine [Korea]; Anacin-3 brand name for acetaminophen [Taiwan]; Anacin New brand name for acetaminophen/caffeine [India]</p>
<p style="text-indent:-2em;margin-left:4em;">Cartia [multiple international markets] may be confused with Cartia XT brand name for dilTIAZem [US]</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Aspirin is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients ≥65 years of age for the primary prevention of cardiovascular disease due to increased risk for major bleeding. A potential for harm and lack of benefit when initiated as primary prevention in older adults is suggested by studies. In older adults already taking for primary prevention, deprescribing should be considered. In addition, aspirin, when used chronically at doses more than 325 mg/day, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients ≥65 years of age (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent) due to increased risk of GI bleeding and peptic ulcer disease in older adults in high-risk category (eg, &gt;75 years of age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Salicylates, when used in pediatric patients &lt;18 years of age with suspicion of viral illness (influenza, chickenpox), are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be used with caution due to risk of Reye syndrome (weak recommendation; very low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F137138"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F137059"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Aspirin may enhance the antiplatelet effect of Abrocitinib.  Management: Do not use aspirin at doses greater than 81 mg/day with abrocitinib during the first 3 months of abrocitinib therapy. The abrocitinib prescribing information lists this combination as contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Salicylates may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Salicylates may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Aspirin. Specifically, alcohol may increase the bleeding risk of aspirin. Alcohol (Ethyl) may diminish the therapeutic effect of Aspirin. Specifically, alcohol may interfere with the controlled release mechanism of extended release aspirin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alendronate: Aspirin may enhance the adverse/toxic effect of Alendronate. Specifically, the incidence of upper gastrointestinal adverse events may be increased <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ammonium Chloride: May increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Aspirin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Salicylates may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Aspirin may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzbromarone: Salicylates may diminish the therapeutic effect of Benzbromarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers (Nondihydropyridine): May enhance the antiplatelet effect of Aspirin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.  Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated. If another combination is used, monitor patients closely for adverse effects. Tachypnea, anorexia, lethargy, and coma have been reported.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: May enhance the antiplatelet effect of Aspirin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Aspirin may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Aspirin may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling states that low dose aspirin could be considered, but the use of antiplatelets are not recommended for stroke prevention in patients with atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexibuprofen: Aspirin may enhance the adverse/toxic effect of Dexibuprofen. Dexibuprofen may diminish the cardioprotective effect of Aspirin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: Salicylates may enhance the adverse/toxic effect of Dexketoprofen. Dexketoprofen may diminish the therapeutic effect of Salicylates. Salicylates may decrease the serum concentration of Dexketoprofen.  Management: The use of high-dose salicylates (3 g/day or more in adults) together with dexketoprofen is inadvisable. Consider administering dexketoprofen 30-120 min after or at least 8 hrs before cardioprotective doses of aspirin to minimize any possible interaction.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Aspirin may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Aspirin may increase the serum concentration of Edoxaban.  Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin. Management: Concurrent use of nasal ketorolac with analgesic doses of aspirin is generally not recommended. If using low-dose, cardioprotective aspirin with nasal ketorolac, monitor the patient closely for evidence of adverse GI effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Systemic): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Salicylates may diminish the therapeutic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Aspirin may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.  Management: Consider avoiding coadministration of methotrexate and salicylates. If coadministration cannot be avoided, monitor for increased toxic effects of methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: Aspirin may enhance the adverse/toxic effect of Nicorandil. Specifically, the risk of gastrointestinal ulceration and hemorrhage may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Aspirin may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective).  Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Management: Nonselective NSAIDs may reduce aspirin's cardioprotective effects. Administer ibuprofen 30-120 minutes after immediate-release aspirin, 2 to 4 hours after extended-release aspirin, or 8 hours before aspirin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Salicylates. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of salicylates and topical NSAIDs is not recommended. If salicylates and topical NSAIDs are coadministered, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Aspirin may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Phosphate: May increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.  Management: Consider avoiding concomitant use of salicylates and pralatrexate. If coadministered, monitor for increased pralatrexate adverse effects. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: Salicylates may diminish the therapeutic effect of Probenecid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Aspirin may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of other Salicylates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: Aspirin may diminish the therapeutic effect of Spironolactone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucroferric Oxyhydroxide: May decrease the serum concentration of Aspirin. Management: Administer aspirin at least 1 hour before administration of sucroferric oxyhydroxide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfinpyrazone: Salicylates may decrease the serum concentration of Sulfinpyrazone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talniflumate: Aspirin may enhance the adverse/toxic effect of Talniflumate.  Management: When possible, consider alternatives to this combination.  Concurrent use is generally not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopental: Aspirin may decrease the protein binding of Thiopental. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: Aspirin may enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in adult patients receiving daily aspirin doses greater than 100-150 mg daily.  Management: Avoid daily aspirin doses greater than 100 mg in adults receiving ticagrelor.  Canadian recommendations are to avoid adult daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiludronate: Aspirin may decrease the serum concentration of Tiludronate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Salicylates may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Specifically, the risk for Reye's syndrome may increase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Avoid as needed use of salicylates in patients taking vitamin K antagonists. Aspirin (80 to 325 mg/day) may be used with warfarin for prevention of cardiovascular events. If coadministering salicylates and vitamin K antagonists, monitor for bledding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F137088"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Food may decrease the rate but not the extent of oral absorption. Benedictine liqueur, prunes, raisins, tea, and gherkins have a potential to cause salicylate accumulation. Fresh fruits containing vitamin C may displace drug from binding sites, resulting in increased urinary excretion of aspirin. Curry powder, paprika, licorice; may cause salicylate accumulation. These foods contain 6 mg salicylate/100 g. An ordinary American diet contains 10-200 mg/day of salicylate. Management: Administer with food or large volume of water or milk to minimize GI upset. Limit curry powder, paprika, licorice.</p></div>
<div class="block rep_considerations drugH1Div" id="F56532910"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Low-dose aspirin has been evaluated to improve live birth rates in patients with antiphospholipid syndrome (APS) diagnosed with recurrent pregnancy loss (Hamulyák 2020; Hamulyák 2021). Recommendations for when to initiate treatment differ between guidelines. Some guidelines initiate aspirin prior to conception, while others prefer use of other agents (heparin or low-molecular-weight heparin) in patients planning to become pregnant (ACR [Sammaritano 2020]); ESHRE [Bender Atik 2018]; EULAR [Andreoli 2017]). Use of low-dose aspirin prior to conception in patients with a history of recurrent pregnancy loss but who are not diagnosed with APS has also been evaluated (Naimi 2021).</p></div>
<div class="block pri drugH1Div" id="F137075"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Salicylate is present in umbilical cord and newborn serum following maternal use of aspirin prior to delivery (Garrettson 1975; Levy 1975; Palmisano 1969); salicylic acid and other metabolites can also be detected in the newborn urine following in utero exposure (Garrettson 1975).</p>
<p style="text-indent:0em;margin-top:2em;">Fetal outcomes are influenced by maternal dose; low dose aspirin (≤150 mg/day) is not associated with the same risks as higher doses and has a positive effect on some pregnancy outcomes (ACOG 2018; Choi 2021; Turner 2020). Adverse effects reported in the fetus following maternal use of high dose aspirin include mortality, intrauterine growth restriction, salicylate intoxication, bleeding abnormalities, and neonatal acidosis. Use of aspirin close to delivery may cause premature closure of the ductus arteriosus. Adverse effects reported in the mother include anemia, hemorrhage, prolonged gestation, and prolonged labor (Corby 1978; Østensen 1998).</p>
<p style="text-indent:0em;margin-top:2em;">Except when used in lower doses for pregnancy-related conditions, maternal use of aspirin should be avoided beginning 20 weeks gestation (FDA Safety Communication 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of aspirin may be altered (Rymark 1994; Shanmugalingam 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Low-dose aspirin is recommended to prevent preeclampsia in patients at risk. The definition of risk factors varies by guideline and dosing varies by country due to dosage form availability (ACOG 2018; FIGO [Poon 2019]; SOGC [Magee 2022]; USPSTF [Davidson 2021]). The American College of Obstetricians and Gynecologists and United States Preventive Services Task Force recommend the use of low-dose aspirin for patients with ≥1 of the following high-risk factors: history of preeclampsia, multifetal gestation, chronic hypertension, type 1 or type 2 diabetes mellitus, renal disease, autoimmune disease (eg, systemic lupus erythematosus, antiphospholipid syndrome), or combinations of multiple moderate risk factors. Low-dose aspirin is also recommended for patients with ≥2 of the following moderate risk factors: nulliparity, BMI &gt;30, family history of preeclampsia, Black race (due to social, rather than biological, factors), lower income, age ≥35 years, personal history factors (eg, low birth weight or small for GA, previous adverse pregnancy outcome, &gt;10-year pregnancy interval), or in vitro conception. Low-dose aspirin may also be considered in patients with ≥1 of the following moderate risk factors: Black race (due to social, rather than biological, factors), lower income (ACOG 2018; ACOG 2021; USPSTF [Davidson 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">In addition to preventing preeclampsia, low-dose aspirin is also recommended to improve other pregnancy outcomes and decrease the risk of thrombosis in patients with a positive antiphospholipid antibody (aPL) test. The addition of heparin or low-molecular-weight heparin may also be needed in patients with obstetric or thrombotic antiphospholipid syndrome (APS). Low-dose aspirin is also recommended for pregnant patients with systemic lupus erythematosus (SLE) (ACR [Sammaritano 2020]; EULAR [Andreoli 2017]; SMFM [Silver 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Low-dose aspirin, in addition to anticoagulation, may be used to prevent thrombosis in pregnant patients with a mechanical heart valve (ACC/AHA [Otto 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Aspirin is not recommended for the treatment of migraine headaches during pregnancy (ACOG 2022).</p></div>
<div class="block mopp drugH1Div" id="F53565518"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, iron studies, ferritin, stools for occult blood, and renal function tests with prolonged therapy. Serum salicylate concentration with chronic use; may not be necessary in Kawasaki disease; <b>Note:</b> Decreased aspirin absorption and increased salicylate clearance has been observed in children with acute Kawasaki disease; these patients rarely achieve therapeutic serum salicylate concentrations; thus, monitoring of serum salicylate concentrations is not necessary in most of these children.</p></div>
<div class="block rerp drugH1Div" id="F53565405"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Timing of serum samples: Peak concentrations usually occur 2 hours after normal doses but may occur 6 to 24 hours after acute toxic ingestion.</p>
<p style="text-indent:-2em;margin-left:4em;">Salicylate serum concentrations correlate with the pharmacological actions and adverse effects observed. See table.</p>
<table border="1" data-table-id="aspirrer" frame="border" rules="all">
<colgroup><col align="center"/>
<col/>
<col/>
</colgroup><thead valign="middle">
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;">Serum Salicylate Concentration</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">Desired Effects</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">Adverse Effects / Intoxication</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">∼100 mcg/mL (SI: ~724 micromole/L)</p></td>
<td align="left">
<p style="text-indent:0em;">Antiplatelet</p>
<p style="text-indent:0em;">Antipyresis</p>
<p style="text-indent:0em;">Analgesia</p></td>
<td>
<p style="text-indent:0em;">GI intolerance and bleeding, hypersensitivity, hemostatic defects</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">150 to 300 mcg/mL (SI: 1,086 to 2,172 micromole/L)</p></td>
<td>
<p style="text-indent:0em;">Anti-inflammatory</p></td>
<td>
<p style="text-indent:0em;">Mild salicylism</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">250 to 400 mcg/mL (SI: 1,810 to 2,896 micromole/L)</p></td>
<td valign="middle">
<p style="text-indent:0em;">Treatment of rheumatic fever</p></td>
<td>
<p style="text-indent:0em;">Nausea/vomiting, hyperventilation, salicylism, flushing, sweating, thirst, headache, diarrhea, and tachycardia</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">&gt;400 to 500 mcg/mL (SI: &gt;2,896 to 3,620 micromole/L)</p></td>
<td></td>
<td>
<p style="text-indent:0em;">Respiratory alkalosis, hemorrhage, excitement, confusion, asterixis, pulmonary edema, convulsions, tetany, metabolic acidosis, fever, coma, cardiovascular collapse, renal and respiratory failure</p></td></tr></tbody></table></div>
<div class="block pha drugH1Div" id="F137053"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Irreversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, via acetylation, which results in decreased formation of prostaglandin precursors; irreversibly inhibits formation of prostaglandin derivative, thromboxane A<sub>2</sub>, via acetylation of platelet cyclooxygenase, thus inhibiting platelet aggregation; has antipyretic, analgesic, and anti-inflammatory properties </p></div>
<div class="block phk drugH1Div" id="F137071"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Immediate release: Platelet inhibition: Nonenteric-coated: &lt;1 hour; enteric-coated: 3 to 4 hours (Eikelboom 2012). <b>Note:</b> Chewing nonenteric-coated or enteric-coated tablets results in inhibition of platelet aggregation within 20 minutes (Eikelboom 2012; Feldman 1999; Sai 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Immediate release: 4 to 6 hours; however, platelet inhibitory effects last the lifetime of the platelet (~10 days) due to its irreversible inhibition of platelet COX-1 (Eikelboom 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Immediate release: Rapidly absorbed in stomach and upper intestine (Eikelboom 2012); Extended-release capsule: Rate of absorption is dependent upon food, alcohol, and gastric pH.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 10 L; readily into most body fluids and tissues; hydrolyzed to salicylate (active) by esterases in the GI mucosa, red blood cells, synovial fluid and blood</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Concentration dependent; as salicylate concentration increases, protein binding decreases: ~90% to 94% (to albumin) at concentrations ≤80 mcg/mL (Rosenberg 1981; Juurlink 2015); ~30% with concentrations seen in overdose (Juurlink 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hydrolyzed to salicylate (active) by esterases in GI mucosa, red blood cells, synovial fluid, and blood; metabolism of salicylate occurs primarily by hepatic conjugation; metabolic pathways are saturable</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Immediate release: 50% to 75% reaches systemic circulation</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Parent drug: Plasma concentration: 15 to 20 minutes; Salicylates (dose dependent): 3 hours at lower doses (300 to 600 mg), 5 to 6 hours (after 1 g), 10 hours with higher doses</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Immediate release: ~1 to 2 hours (nonenteric-coated), 3 to 4 hours (enteric-coated) (Eikelboom 2012); Extended-release capsule: ~2 hours. <b>Note:</b> Chewing nonenteric-coated tablets results in a time to peak concentration of 20 minutes (Feldman 1999). Chewing enteric-coated tablets results in a time to peak concentration of 2 hours (Sai 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (75% as salicyluric acid, 10% as salicylic acid)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F137078"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ascor | Asiapirine | Aspegic | Aspimed | Aspirin Nuseal | Aspirin protect | Aspro | Asrivo | Dispril | Ecosprin | Jusprin | Nu Seals | Rivo | Rivo Micro</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">A.a.s. | Acido acetil salicilico | Acido acetilsalicilico northia | Adiro ap | Aspimed | Aspirina asat | Aspirina fabra | Aspirina fecofar | Aspirina ginsex | Aspirina ginsex fuerte | Aspirina lacefa | Aspirina Prevent | Aspirina Vent-3 | Aspirina-g | Aspirinetas | Bayaspirina | Bayaspirina forte | Bayaspirina preven | Cardio vent3 | Cardioaspirina | Ecotrin | Egalgic | Geniol ap | Geniol prevencion | Geniol sc | Geniol sc 500 mg | Geniol sc sin cafeina | Geniolito | Isaspirina | Isaspirina preventiva | Nuevapina | Nuevapina cardio</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Acekapton | Acid.acetylsalicylic | Aspiricor | Aspirin | Aspirin protect | Aspro | Aspro classic | Ass | Ass genericon | CorProtect | Herz ass | Herzschutzass | Thrombo ass | Thrombostad | Thrombostad protect | Togal | Tromalyt Ass | Trombo ASS</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amcal aspirin | Apohealth cardio aspirin | Aspirin | Aspro | Astrix | Bayer aspirin | Cardasa | Cartia | Chemists' own low dose aspirin | Chemmart pharmacy aspirin | Dbl aspirin | Disprin | Guardian aspirin | Mayne pharma aspirin | Nyal low dose aspirin | Pharmacist formula cardio aspirin | Pharmacy action low dose aspirin | Pharmacy care aspirin | Soul pattinson aspirin | Spren | Terry white chemists dispersible aspirin | Trust aspirin ec | Trust thrombix low dose aspirin | Vincents</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aciprin-cv | Angiprin | Ascard | Aspin | Aspirin | Caid | Cardoprin | Carva | Disprin | Disprin Cv | Ecosprin | Encoprin | Encopyrin | Eras | Erasprin | Genasprin | Mysprin | S Pirin | Solrin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Acenterine | Acetylsalicylic acid krka | Acetylsalicylic acid ratiopharm | Asa apotex | Asa eg | Asa Sandoz | Asaflow | Asamed | Aspirine | Cardioaspirine | Cardioflow | Dispril | Rhodine | Rhonal | Tampyrine</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Acide acetylsalicylique</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Acard | Acessal protect | Acetylin | Acetylin protect | Acetysal | Acetysal cardio | Anopyrin | Apiri | Asa krka | Asperan | Aspetax | Aspetax protect | Aspetin | Aspirex | Aspirin | Aspirin direkt | Aspirin protect | Aspisevt | Aspizal | Cardiopirin | Cardiosalin protect | Ruvexin | Thrombo ass | Trombogard | Tusari | Unirex | Zerotromb</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Aas | Aas protect | Aasedatil | Aceticil | Acetildor | Acido acetilsalicilico | Alidor | Analgesin | Antifebrin | As-med | Ascedor | Asetisin | Aspirina | Aspirina Prevent | Assetil | Buferin | Bufferin cardio | Caas | Cardio aas | Cimaas | Dormec | Ecasil | Febridor | Hipotermal | Melhoral infantil | Ronal | Salicetil | Salicil | Salicin | Salipirin | Salitil | Sedalive | Sifass</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Asa | Aspirin | Aspirin cardio | Ass | Ass Cardio | Ass cardio axapharm | Ass cardio mepha | Ass Cardio Spirig | Ass-mepha | Cardiax ass | Cardioral | Colfarit | Contra-Schmerz ASS | Coop vitality acetylsalicylic acid | Thrombace neo | Togal ass</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Acide acetylsalicylique ubigen | Aspirine | Aspirine du rhone | Cardioaspirine</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Adiro | Aspirina | Cardioaspirina | Disgren | Dominal | Ecotrin | Ewin | Fluicor | Hassapirin | Thrombo as</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A rong | An ni tuo | Arginine aspirin | Aspirin | Bamyl | Bayaspirin | Bo er xin | Bokey | Jie ning | Original | Xie mei da | Xin dong | Xin hui | Yi xin xue</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acido acetil salicilico | Acido acetilsalicilico | Asa | Asa mk | Asacard | Asaplaq | Asawin | Aspirina | Aspirina ultra | Aspirub | Cardioaspirina | Eclamp | Ecotrin | Entrophen | Plaquesyn | Rhonal | Rhonalito | Tromalyt | Violdol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Acygal | Acylpyrin | Algirin | Anopyrin | Aspirin | Astrix | Cardioral | Carlagirin | Carsaxa | Manoass | Micristin | Stacyl | Vasopirin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Acesal | Acetylsalicyloc acid adgc | Apovital apo ass | Aspirin | Aspirin direkt | Aspirin N | Aspirin protect | Aspirine | Ass | Ass 1 a pharma | Ass 500 fair med | Ass abz tah | Ass al | Ass aristo | ASS Atid | ASS Axcount | Ass axicur | Ass CT | Ass dexcel | Ass dura | Ass Elac | Ass fair med | Ass gamma | Ass hexal | Ass ipa | Ass Isis | Ass kreuz | Ass lich | Ass medibond | Ass Molimin | Ass opt | Ass phamos | Ass Protectid | Ass puren | Ass ratiopharm | Ass Sandoz | Ass Sophien | Ass stada | ASS TAD protect | Ass tah | Ass wepa | Ausbuettels ass | Colfarit | Docpelin ASS | Gib Ass | Godamed | Godamed tah | Herz ass | Herz Ass 1 A Pharma | Miniasal | Santasal N | Temagin Ass | Thomapyrin akut | Thrombass | Togal ass | Werodon ass</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Aspirin | Hjerdyl | Hjertemagnyl | Hjertemin | Magnyl</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aasp cardiologica df | Acido acetil salicilico | Acido acetilsalicilico | Asawin | Aspialfa | Aspicard | Aspilat | Aspiridom | Aspirina | Aspirina advanced | Aspirina Cardiologica | Aspirina infantil | Asprim | Cardet | Cardioaspirina | Cardiomejoral | Cetrin | Cor Asa | Corachem | Coralat | Coralegre | Corasa | Coraspir | Ecotrin | Etipirin | Europirina | Piricard | Tromalyt</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acido acetilsalicilico labovida | Antiplac | Aristopirin | Asa mk | Asawin | Aspirina | Aspirina direkt | Blaqueta | Bufferin | Cardioaspirina | Cardionil | Entrophen | Fonazil | Rhonal</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Acesal | Acidum acetylsalicylicum | Albyl minor | Asa krka | Aspirin | Aspirin cardio | Aspirin disper | Aspro | Aspro-regular | Asprovit | Asrivo | Ass ratiopharm | Disperin | HerzASS | Hjertemagnyl | Magnyl | Thrombo ass | Trombyl</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Acpophar | Aggrex | Alexoprin | Alexoprine | Aspain | Aspeol | Aspico | Aspirin | Aspirin 81 | Aspirin aug pharma | Aspirin chemipharm | Aspirin protect | Aspo | Aspocard | Aspocid | Asponasr | Asprin | Asprotect | Cardiprin | Ecoprin | Ezacard | Jusprin | Rivo | Rivo Micro</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">A.a.s. | Acido acetilsalicilico | Acido acetilsalicilico accord | Acido acetilsalicilico actavis | Acido acetilsalicilico alter | Acido acetilsalicilico apotex | Acido acetilsalicilico cinfa | Acido acetilsalicilico kern pharma | Acido acetilsalicilico madaus | Acido acetilsalicilico mylan | Acido acetilsalicilico pensa | Acido acetilsalicilico ratiopharm | Acido acetilsalicilico stada | Acido acetilsalicilico tarbis | Acido acetilsalicilico teva | Adiro | Aspirina | Aspirina adultos | Aspirina infantil | Bartal | Bioplak | Rhonal | Sedergine | Tromalyt</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Aceprin | Aspir | Aspirem | Salisal | Salospir</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Acetard | Acetosal | Acetylsalicylic acid Leiras | Acid Acetylsalicylic | Asa-lannacher | Asa-ratiopharm | Asacard | Asalent | Aspirin | Aspro | Avasyl | Bartal | Disperin | Magnecyl | Primaspan | Thrombo Asa</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Acide acetylsalicylique eg | Acide acetylsalicylique mylan | Aspirine | Aspirine 325 mg | Aspirine arrow | Aspirine bayer | Aspirine du rhone | Aspirine Medication Familiale | Aspirine merck | Aspirine nicholas | Aspirine protect | Aspirine Ratiopharm | Aspirine richard | Aspirisucre | Aspro | Resitune | Rhonal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Aspirin | Aspirin almus | Aspirin arrow | Aspirin aurum | Aspirin cox | Aspirin cupal | Aspirin dc | Aspirin farmitalia | Aspirin galpharm | Aspirin kent | Aspirin sandoz | Aspirin sterwin | Aspirin zanza | Aspro | Bayer aspirin | Beechams aspirin | Boots aspirin | Caprin | Disprin | Enprin | Flamasacard | Genasprin | Gencardia | Levius | Micropirin | Nu Seals | Nu seals aspirin | Nu seals cardio | Pharmacin | Postmi | Q a | Resprin</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Danacin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aspirin | Aspirin e.c | Salospir</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Aceprin | Apo Asa | Asp | Aspi Cor | Aspilets | Aspirin | Aspirin bayer | Astrix | Cartia | Disprin | Ecopirin | Ecotrin | Heartia | Qualitea | Uni-Acetil</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Andol | Andol pro | Aska | Aska pro | Aspirin | Aspirin direkt | Aspirin protect | Cardiopirin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Acizalep | Asa krka | Asa protect pharmavit | Asactal | Asatrin teva protect | Aspirin | Aspirin protect | Asprevin | Aspro | Astrix | Colfarit | Cordisal | Corpyrin | Huma asa | Istopirin | Micristin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Acetosal | Aptor | Ascardia | Aspilets | Aspimec | Aspirin bayer | Astika | Bodrexin | Cafenol | Cardio aspirin | Cartylo | Farmasal | Gramasal | Mikras | Miniaspi | Molasic | Naspro | Norspirinal | Procardin | Restor | Rhonal | Thrombo aspilets</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Aspirin | Aspirin Krka | Aspirin nuseals | Aspro | Bayer aspirin | Caprin | Nuprin | Resprin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Acetosal | Aspirin | Cartia | Ecoprin | Godamed | Micropirin | Rhonal | Tevapirin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alcylic | Asa | Asalyte | Ascad | Asicom | Aspent | Aspicot | Aspin | Aspirin | Aspitec | Aspro | Atherid | Beat | Covasa | Cv-Sprin | Delisprin | Disprin | E-prin | Ecosprin | Gra | Lodosprin | Loprin | M spirin | Mazoral | Nusprin | Sprin | Sprintas | Tinysprin | Zosprin</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Aspin | Aspirin mdi</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Hjartamagnyl</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Acesal | Acido acetilsalicilico | Acido acetilsalicilico Aristo | Acido acetilsalicilico aurobindo | Acido acetilsalicilico doc generici | Acido acetilsalicilico eg | Acido acetilsalicilico mylan | Acido acetilsalicilico sandoz | Acido acetilsalicilico tecnigen | Asa | Aspirina | Aspirina 05 | Aspirina rapida | Aspirinetta | Aspro | Cardioaspirin | Cardioral | Cemirit | Flectadol | Gentazetan | Kilios | Noalgesin | Vivin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Adiprin | Aspirin | Aspirin protect | Aspirin protect EC | Aspro | Asrivo | Remin | Salisal</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Analexin | Aspirin | Aspirin arax | Aspirin bayer | Aspirin kn | Aspirin koshodo | Aspirin mitsubishi | Aspirin mohan | Aspirin nisshin kyorin | Aspirin yamakawa | Astoplen | Bayaspirin | Chuanon | Fulmaide | Nichiaspirin | Rhonal | Salitison | Sanspomin | Serubon | Zenaspirin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Acemol | Ascard | Asp | Aspirin | Aspirin cardio | Aspro | Cardi | Cardilife | Cardisprin | Corsprin | Dawasprin | Delisprin | Disprin | Ecosprin | Esprin | Junior aspirin | Totoprin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acerin | Alpirin | Anapirin | Asap | Asatop | Ascool | Asp | Aspharm | Aspiba | Aspid | Aspidid | Aspil | Aspirin | Aspirin bayer | Aspirin chongkundang | Aspirin daejung | Aspirin direkt | Aspirin protect | Aspirin samwoo | Aspirin taerim | Aspirin yungjin | Asseven | Astect | Astection | Asteric | Asterin | Aukopirin | Chodang aspirin | Circlevein | CMG aspirin | Cosmax aspirin | Daewon aspirin heart | Daewoongbio aspirin | Entas | Glo aspirin | Gloaspirin | Hanlim aspirin | Hanmi aspirin | Hawon aspirin | Ispirin | Kukje aspirin | Kyungdong aspirin | Myungmoon aspirin | Newspirin | Nexpin | Prime aspirin | Rhonal | Rinas | Rinpis | Samik aspirin | Samjin aspirin | Samsung aspirin | Seoul Aspirin | Union aspirin | Vasopirin | White aspirin | Yooyoung aspirin | Youngil aspirin | Yuhan aspirin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Aspirin | Aspirin Nuseal | Aspirin protect | Disprin 81 | Jusprin | Nu Seals | Rivo | Rivo Micro | Salisal</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aspi Cor | Aspicot | Aspin | Aspirin | Aspirin protect | Asprotect | Asprothin | Buffered Aspirin | Caprin | Dolean Ph 8 | Nu Seals | Rhonal</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Abrea | Acesal | Acetylsalicylic acid Grindex | Acetylsalicylic acid siromed | Acetysal | Acidum acethylsalicylicum | Acidum acetylsalicylicum | Acylpyrin | Anopyrin | Apo Asa | Arocora | Artelac | Aspirin | Aspirin cardio | Aspirin EC | Aspirin protect | Aspomy | Aspro | Ass | Cardiopirin | Disprin | Heartisan | Herz ass | Hjertemagnyl | Magnyl | Micristin | Neoacetilsalicilas | New asper | Polopyrina | Provapirin | Thrombo ass</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Asa eg | Asaflow | Aspirine | Aspro | Ass | Cardioaspirine | Dispril | Rhodine | Tampyrine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Acesal | Acetilin | Acetilsalicilskabe | Acetysal | Acidum acetylsalicum | Acylpyrin | Anopyrin | Apo Asa | Asaphen | Aspecard | Aspecardum | Aspirin | Aspirin analgesic | Aspirin cardio | Aspirin low | Aspirin tri-buffer | Aspirin usa | Aspomy | Aspro | Ass | Ass bonfal | Ass gamma | Cardiopirin | Disprin | Heartisan | HerzASS | Micristin | New asper | Polopyrina | Thrombo ass | Vasopirin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Aspirine | Aspirine bayer | Aspro | Cardioflex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acetiben | Acetin | Acid.ac.sal.gi | Acido acetilsalicilico | Acido acetilsalicilico bruluagsa | Acido acetilsalicilico kendrick | Acido acetilsalicilico landsteiner | Acitab | Adiro | Antacsal | Asa | Asawin | Aspirina | Aspirina advanced | Aspirina infantil | Aspirina junior | Aspirina protect | Aspitak P | Axal | Baleptil lr | Dalabul | Disprina | Doloquim | Doloquim lr | Labysal | Limzeid | Limzeid lr | Midolen | Prasraam | Syxdolan</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Aac | Aceprin | Alka-seltzer | Aspirin | Aspirin cardio | Aspril | Cardiprin | Casprin | Cortal | Disprin | Dusil | Dynapil | Soluble aac | Tooprin | Vispirin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Acetysalicylic acid | Aspirin | Aspirin cardio | Avro aspirin | Aziprin | Emprin | Kp acetylsalicylic | Kunimed aspirin | Lesaprin | Lospirin | Micropirin | Nasmoprin | Surespirin | Vasoflo | Vasoprin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Acetylsalicylzuur | Acetylsalicylzuur cardio | Acetylsalicylzuur dumex cardio | Acetylsalicylzuur neuro | Aspirine | Aspirine ec | Aspirine protect | Aspro | Aspro cardio | Aspro neuro | San acetylsal.zuur</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Acetylsalicylsyre teva | Acetylsalisylsyre | Acetylsalisylsyre actavis | Acetyratio | Aspirin | Aspirin cardio | ASS Protect | Bamycor | Globentyl | Globoid | Magnyl | Novid</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Aspec | Aspirin | Aspro | Bayers aspirin | Cartia | Disprin | Ecotrin | Ethics Aspirin | Heartcare aspirin | TerryWhite Chemmart Low Dose Aspirin</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Aspilo | Jusprin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Aas | Aascard | Acido acetilsalicilico | Asawin | Aspirina | Assa-81 | Aterosyn | Cardio aliv | Cardioaspirina | Cardiopress | Cardioton | Cardiotrin | Cardipill | Cor Asa | Ecotrin | Mejoral descaf | Microass | Plack | Tromalyt</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Aceprin | Anthrom | Asaped | Asaprim | Aspec-ec | Aspen | Aspilets | Aspilets ec | Aspin | Aspirin | Aspitor | Asthromed | Bayer aspirin | Bayprin | Besprin | Cor-30 | Cor-80 | Cortal | Enteroprin | Philprin | Saphrin | Scheeprin | Tromcor</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Anaprin | Anticlot | Apiscot | Asa | Ascard | Askprin | Aslow 81 | Aspirin | Aspisafe | Aspro | Cardrin | Cv | Disprin | Disprin Cv | Doloprin | Evoprin | Heartline | Loprin | Mactoprin | Masprin | Myprin | Novoprin | Nu Seals | Panarin | Prosperin | Tesla | Vin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Abrea | Acard | Acesan | Acylpyrin | Alepton | Ampiryna | Anacard protect | Anopyrin | Apyrin | Asa | Asaltec | Asopiryna | Aspicont | Aspifox | Aspirin | Aspirin activ | Aspirin cardio | Aspirin pro | Aspirin protect | Aspotabs | Bestpirin | Cardiofil | Cardiopirin | Cardioteva | Encopirin | Entacet | Entreik | Etopiryna pro | Galocard | Gripblocker | Grypostop control | Hascopiryn | Hascopiryn cardio | Lecardi | Maxipirin | Miraspryn | Nipas | Novasen | Novaspryn | Polocard | Polopiryna | Polopiryna max | Proficar | Rhonal | Salpirin | Ultrapiryna | Ultrapiryna forte | York aspirin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Anacin 81 | Asp | Aspirin | Aspirin buffered | Aspirina | Bayer aspirin | Bayer aspirin regimen | Easprin | Ecotrin | Ecotrin maximum strength | Ninoprin | NobleAid aspirin | St. joseph aspirin | Tri-buffered aspirin | Zorprin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">A-a-s | Ac.acetilsa | Acido acetilsalicilico | Acido acetilsalicilico Aristo | Acido acetilsalicilico bluepharma | Acido acetilsalicilico generis | Acido acetilsalicilico Krka | Acido acetilsalicilico mylan | Acido acetilsalicilico pharmakern | Acido acetilsalicilico Tolife | Asp | Aspifantil | Aspirina | Aspirina gr | Aspirina mastigavel | Aspven GR | Ass | Cartia | Gripal | Salicylina | Stacitil | Toldex | Tromalyt</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aas 100 | Aas 125 | Aas 500 | Aas 81 | Acido acetil salicilico | Acido acetil salicilico dallas | Acido acetil salicilico dutriec | Acido acetil salicilico guayaki | Acido acetil salicilico heisecke | Acido acetil salicilico lasca | Acido acetil salicilico pasteur | Algina | Aspirina | Aspirina forte | Aspirinetas | Cardio contradol | Cardio salysil | Cardioaspirina | Eximpirina | Geniol cardio | Geniolito | Grifantil | Salysil | Tri buffered cardio</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Adiprin | Almus | Aspirin Adult | Aspirin Protect | Bayer Aspirin | Coraspin | Disprin | Ecopirin | Jusprin | Nu-Seals | Salisal</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Acesal | Acesil t | Acid acetilsalicil krka | Acid acetilsalicilic biofarm | Acid acetilsalicilic labormed | Acid acetilsalicilic richter | Acid acetilsalicilic solacium | Acid acetilsalicilic t biofarm | Acid acetilsalicilic t sanosan | Acid acetilsalicilic tamponat solacium | Acid acetilsalicilic zentiva | Acisalic | Asaline | Asaprin | Asaprin cardio | Asaprin t | Aspifox | Aspimax | Aspimax cardio | Aspirin | Aspirin cardio | Aspirin direkt | Aspirin protect | Aspitor cardio | Cartia | Europirin | Protecardin | Rompirin e | Santepirin | Vasopirin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Acecardol | Acetilsalicylovaya kislota | Acetylcardio | Acetylsalicylic acid cardio | Acetylsalicylic acid lekt | Acetysal | Acidum acetylsalicum | Acidum acetylsalicum york | Acylpyrin | Anopyrin | Arphasetin | Ascalcin | Ask-cardio | Aspecard | Aspicard | Aspicor | Aspikard | Aspikor | Aspilyte | Aspinat | Aspinat cardio | Aspirin | Aspirin cardio | Aspirin miltom | Aspirin quality | Aspirin york | Aspivit | Aspro | Cardiask | Cardiopirin | Cardioprin | Colfarit | New asper | Nextrim fast | Sanovasc | Terapin | Thrombo ass | Thrombosten | Trombogard 100 | Trombopol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Aspicard | Aspirin | Aspro | Azera | Disprin 81 | Entrophen | Jusprin | Novasen | Rivo</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Acetylsalicylic acid bluefish | Acetylsalicylsyra abece | Acetylsalicylsyra actavis | Acetylsalicylsyra apofri | Acetylsalicylsyra gl pharma | Acetylsalicylsyra orifarm | Acetylsalicylsyra teva | Albyl minor | Asaferm | Aspirin | Bamycor | Bamyl | Dispril | Magnecyl | Trombyl</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alka-seltzer | Aspirin | Aspirin bayer | Aspirin cardio | Aspro | Cartia | Disprin | Dusil | Ecotrin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Andol | Aspirin | Aspirin direkt | Aspirin Protec | Baludon | Cardiopirin | Nu Seals</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Acylpyrin | Algirin | Anopyrin | Aspirin | Aspirin protect | Cardioral | Carlagirin | Carsaxa | Gerasa | Preventax | Stadapyrin | Vasopirin</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Aspi | Aspirin | Aspiu | Empirin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">A s a | Actorin | Anassa | Ant | Arc baby | Arpisin | Asatab | Ascot | Aslac | Aslac b | Aspa | Aspac | Aspaco | Aspent-m | Aspilets | Aspirin | Aspirin bayer | Asprex | Asrin | Asrin B | Asteric | B Aspirin | Babyrin | Chewaprin | Comoprin | Disprin | Empirin | Entas | Entrarin | Exprin | Fob Rin | Infarcard | Nanapirin | Oxy | Pirin | Salapyrin | Seferin-10 | Seferin-5 | SP | Tamjai | Thiocin R | Zaap</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Actalgine | Aspirine | Aspirine ph 8 | Cardiocine | Rhonal | Trombyl</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Algo | Asegan | Asinpirine | Aspapirine | Aspinal | Aspirin | Ataspin | Babypyrin | Coraspin | Dispril | Ecopirin | Ecopirin pro | Isaspin | Notras | Opon | Pharmaspirin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Acid Acetylsalicylic | Anbinin | Anpisol | Ansin | Aspirin | Asplatelet | Astar | Baby aspirin | Cardiopirin | Comfort | Disprin | Ducodon | Ecotrin | Espin e.m. | Fosen | Hocoton | Kersan | Lopirin | Nimape | Relaxday | Ropal | Sintan | Stin | Tapal | Tapal for children | Toderin | Un impede</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Acard | Acecardin | Acecor Cardio | Acetilin | Acetysal | Acidum acetylsalicylic | Acylpyrin | Anopyrin | Apo Asa | Asacil A | Asaphen | Ask teva | Aspecard | Aspenorm | Aspeter | Aspirin | Aspirin cardio | Aspirin Upsa | Asprocol | Cardio dar | Cardisave | Fitoaspirin | Kardiseyv | Lowspirin | Magnicor | New asper | Pms Asa ec | Therapin | Thrombo ass</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agosprin | Aspirem | Aspirin | Aspirin bp | Bayer aspirin cardio | Cardisprin | Casprin | Ecorin 75 | Jusprin | Kamspro</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">A.a.s. | Aas | Aas prevent | Aas protect | Adiro | Aspirina | Aspirina forte | Aspirinetas | Cardioaspirina | Cardioral | Cardiotina | Cuorpirin | Engedol asp | Rhodine | Tribuff | Vipirina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acido acetil salicilico | Acido acetilsalicilico | Asaprol | Aspiretina | Aspirina | Aspirina Bayer | Asprinil | Azacard | Biospirina | Caloxpirina | Cardipirina | Coraspirina | Norprim | Rhonal | Wellsprin</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Aspirin ph8</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspirin | Bayer aspirin | Bayer aspirin cardio | Be-tabs aspirin | Gulf Aspirin | Junior asprin | Lo-aspirin | Myoprin | Pain expeller | Soluspirin cv</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Asp | Aspikant | Aspirin | Aspro | Bayer aspirin cardio | Disprin | Ecorin 75 | Eprin | Loprin | Repisprin | Safecoat Aspirin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Aspirin | Aspirin protect | Cafemol children's size | Disprin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35368325">
<a name="35368325"></a>Abraham NS, Barkun AN, Sauer BG, et al. American College of Gastroenterology-Canadian Association of Gastroenterology clinical practice guideline: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period.<i> J Can Assoc Gastroenterol.</i> 2022;5(2):100-101. doi:10.1093/jcag/gwac010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/35368325/pubmed" id="35368325" target="_blank">35368325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Abramson.1">
<a name="Abramson.1"></a>Abramson SB. Aspirin: Mechanism of action, major toxicities, and use in rheumatic diseases. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24678937">
<a name="24678937"></a>Adams DH, Popma JJ, Reardon MJ, et al; US CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. <i>N Engl J Med</i>. 2014;370(19):1790-1798. doi:10.1056/NEJMoa1400590<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24678937/pubmed" id="24678937" target="_blank">24678937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26320112">
<a name="26320112"></a>Adler Y, Charron P, Imazio M, et al; ESC Scientific Document Group. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). <i>Eur Heart J</i>. 2015;36(42):2921-2964. doi:10.1093/eurheartj/ehv318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26320112/pubmed" id="26320112" target="_blank">26320112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315275">
<a name="22315275"></a>Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e669S-e690S. doi:10.1378/chest.11-2307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22315275/pubmed" id="22315275" target="_blank">22315275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29939940">
<a name="29939940"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 743: Low-dose aspirin use during pregnancy. <i>Obstet Gynecol</i>. 2018;132(1):e44-e52. doi:10.1097/AOG.0000000000002708<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/29939940/pubmed" id="29939940" target="_blank">29939940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists (ACOG) Practice Advisory. Low-dose aspirin use for the prevention of preeclampsia and related morbidity and mortality. 2021.  https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/12/low-dose-aspirin-use-for-the-prevention-of-preeclampsia-and-related-morbidity-and-mortality. Accessed November 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2021">
<a name="ADA.2021"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30536394">
<a name="30536394"></a>American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice [published correction appears in <i>Headache</i>. 2019;59(4):650-651]. <i>Headache</i>. 2019;59(1):1-18. doi:10.1111/head.13456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/30536394/pubmed" id="30536394" target="_blank">30536394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APS.1">
<a name="APS.1"></a>American Pain Society (APS). <i>Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>. 7th ed. Glenview, IL: 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23732713">
<a name="23732713"></a>Anderson DR, Dunbar MJ, Bohm ER, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. <i>Ann Intern Med</i>. 2013;158(11):800-806. doi:10.7326/0003-4819-158-11-201306040-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/23732713/pubmed" id="23732713" target="_blank">23732713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29466159">
<a name="29466159"></a>Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. <i>N Engl J Med</i>. 2018;378(8):699-707. doi:10.1056/NEJMoa1712746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/29466159/pubmed" id="29466159" target="_blank">29466159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27457513">
<a name="27457513"></a>Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. <i>Ann Rheum Dis</i>. 2017;76(3):476-485. doi:10.1136/annrheumdis-2016-209770<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/27457513/pubmed" id="27457513" target="_blank">27457513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aranki.1">
<a name="Aranki.1"></a>Aranki S, Maltais S, Toeg HD. Medical therapy to prevent complications after coronary artery bypass graft surgery. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23713086">
<a name="23713086"></a>Armstrong MJ, Gronseth G, Anderson DC, et al. Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2013;80(22):2065-2069.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/23713086/pubmed" id="23713086" target="_blank">23713086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30879355">
<a name="30879355"></a>Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Circulation</i>. 2019;140(11):e649-e650]. <i>Circulation</i>. 2019;140(11):e596-e646. doi:10.1161/CIR.0000000000000678<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/30879355/pubmed" id="30879355" target="_blank">30879355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007;20-136.</div>
</li>
<li>
<div class="reference">
                  Aspirin [prescribing information]. Morristown, NJ: Bayer Corporation.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23004922">
<a name="23004922"></a>Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. <i>Chronobiol Int.</i> 2013;30(1-2):260-279. doi:10.3109/07420528.2012.717455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/23004922/pubmed" id="23004922" target="_blank">23004922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7098450">
<a name="7098450"></a>Bailey DN, Weibert RT, Naylor AJ, Shaw RF. A study of salicylate and caffeine excretion in the breast milk of two nursing mothers. <i>J Anal Toxicol</i>. 1982;6(2):64-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/7098450/pubmed" id="7098450" target="_blank">7098450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14583068">
<a name="14583068"></a>Bar-Oz B, Bulkowstein M, Benyamini L, et al. Use of antibiotic and analgesic drugs during lactation. <i>Drug Saf</i>. 2003;26(13):925-935. doi:10.2165/00002018-200326130-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/14583068/pubmed" id="14583068" target="_blank">14583068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16781485">
<a name="16781485"></a>Barbui T, Finazzi G. Evidence-based management of polycythemia vera.<i> Best Pract Res Clin Haematol.</i> 2006;19(3):483-493. doi:10.1016/j.beha.2005.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/16781485/pubmed" id="16781485" target="_blank">16781485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29515238">
<a name="29515238"></a>Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i>. 2018;32(5):1057-1069. doi:10.1038/s41375-018-0077-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/29515238/pubmed" id="29515238" target="_blank">29515238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bayer.1">
<a name="Bayer.1"></a>Bayer Chewable Low Dose Aspirin 81 mg (aspirin) [prescribing information]. Whippany, NJ: Bayer Corporation; December 2019.</div>
</li>
<li>
<div class="reference">
                  Bayer Regular Strength Aspirin 325 mg Safety Coated Caplets (aspirin) [prescribing information]. Whippany, NJ: Bayer Corporation; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bayer.3">
<a name="Bayer.3"></a>Bayer Safety Coated 81 mg (Regimen) (aspirin) [prescribing information]. Whippany, NJ: Bayer Corporation; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22621626">
<a name="22621626"></a>Becattini C, Agnelli G, Schenone A, et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism [published correction appears in <i>N Engl J Med</i>. 2012;367(16):1573]. <i>N Engl J Med</i>. 2012;366(21):1959-1967. doi:10.1056/NEJMoa1114238<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22621626/pubmed" id="22621626" target="_blank">22621626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31486805">
<a name="31486805"></a>Bender Atik R, Christiansen OB, Elson J, et al; ESHRE Guideline Group on RPL. ESHRE guideline: recurrent pregnancy loss. <i>Hum Reprod Open</i>. 2018;2018(2):hoy004. doi:10.1093/hropen/hoy004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31486805/pubmed" id="31486805" target="_blank">31486805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31496752">
<a name="31496752"></a>Blanca-Lopez N, Soriano V, Garcia-Martin E, Canto G, Blanca M. NSAID-induced reactions: classification, prevalence, impact, and management strategies. <i>J Asthma Allergy</i>. 2019;12:217-233. doi:10.2147/JAA.S164806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31496752/pubmed" id="31496752" target="_blank">31496752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25773268">
<a name="25773268"></a>Bonaca MP, Bhatt DL, Cohen M, et al; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. <i>N Engl J Med</i>. 2015;372(19):1791-1800. doi:10.1056/NEJMoa1500857<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25773268/pubmed" id="25773268" target="_blank">25773268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4036839">
<a name="4036839"></a>Bradley LM, Midgley FM, Watson DC, et al. Anticoagulation Therapy in Children With Mechanical Prosthetic Cardiac Valves. <i>Am J Cardiol</i>. 1985;56(8):533-535.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/4036839/pubmed" id="4036839" target="_blank">4036839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23121403">
<a name="23121403"></a>Brighton TA, Eikelboom JW, Mann K, et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. <i>N Engl J Med</i>. 2012;367(21):1979-1987. doi:10.1056/NEJMoa1210384<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/23121403/pubmed" id="23121403" target="_blank">23121403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brilinta.1">
<a name="Brilinta.1"></a>Brilinta (ticagrelor) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21282493">
<a name="21282493"></a>Brott TG, Halperin JL, Abbara S, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Stroke Association; American Association of Neuroscience Nurses; American Association of Neurological Surgeons; American College of Radiology; American Society of Neuroradiology; Congress of Neurological Surgeons; Society of Atherosclerosis Imaging and Prevention; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society of NeuroInterventional Surgery; Society for Vascular Medicine; Society for Vascular Surgery; American Academy of Neurology and Society of Cardiovascular Computed Tomography. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. <i>Stroke</i>. 2011;42(8):e464-e540. doi:10.1161/STR.0b013e3182112cc2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/21282493/pubmed" id="21282493" target="_blank">21282493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20505173">
<a name="20505173"></a>Brott TG, Hobson RW 2nd, Howard G, et al; CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis [published corrections appear in <i>N Engl J Med</i>. 2010;363(2):198; <i>N Engl J Med</i>. 2010;363(5):498]. <i>N Engl J Med</i>. 2010;363(1):11-23. doi:10.1056/NEJMoa0912321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/20505173/pubmed" id="20505173" target="_blank">20505173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32865376">
<a name="32865376"></a>Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. <i>N Engl J Med</i>. 2020;383(15):1447-1457. doi:10.1056/NEJMoa2017815<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/32865376/pubmed" id="32865376" target="_blank">32865376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15837265">
<a name="15837265"></a>Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. <i>J Am Coll Cardiol</i>. 2005;45(8):1295-1301. doi:10.1016/j.jacc.2005.01.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/15837265/pubmed" id="15837265" target="_blank">15837265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carapetis.1">
<a name="Carapetis.1"></a>Carapetis J, Brown A, Maguire G, Walsh W. <i>The Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease</i>. 2nd ed. Casuarina, NT, Australia: RHD Australia, Menzies School of Health Research; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10643705">
<a name="10643705"></a>Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. <i>Arthritis Rheum</i>. 2000;43(1):103-108. doi:10.1002/1529-0131(200001)43:1&lt;103::AID-ANR13&gt;3.0.CO;2-C<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/10643705/pubmed" id="10643705" target="_blank">10643705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11752357">
<a name="11752357"></a>Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. <i>N Engl J Med</i>. 2001;345(25):1809-1817. doi:10.1056/NEJMoa003199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/11752357/pubmed" id="11752357" target="_blank">11752357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29908361">
<a name="29908361"></a>Cea Soriano L, Lanas A, Soriano-Gabarró M, García Rodríguez LA. Incidence of upper and lower gastrointestinal bleeding in new users of low-dose aspirin. <i>Clin Gastroenterol Hepatol</i>. 2019;17(5):887-895.e6. doi:10.1016/j.cgh.2018.05.061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/29908361/pubmed" id="29908361" target="_blank">29908361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chan.1">
<a name="Chan.1"></a>Chan A. NSAIDs (including aspirin): role in prevention of colorectal cancer. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 4, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21899409">
<a name="21899409"></a>Chimowitz MI, Lynn MJ, Derdeyn CP, et al; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. <i>N Engl J Med</i>. 2011;365(11):993-1003. doi:10.1056/NEJMoa1105335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/21899409/pubmed" id="21899409" target="_blank">21899409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33795180">
<a name="33795180"></a>Choi YJ, Shin S. Aspirin prophylaxis during pregnancy: a systematic review and meta-analysis. <i>Am J Prev Med</i>. 2021;61(1):e31-e45. doi:10.1016/j.amepre.2021.01.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/33795180/pubmed" id="33795180" target="_blank">33795180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7449246">
<a name="7449246"></a>Clark JH, Wilson WG. A 16-day-old breast-fed infant with metabolic acidosis caused by salicylate. <i>Clin Pediatr (Phila)</i>. 1981;20(1):53-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/7449246/pubmed" id="7449246" target="_blank">7449246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-364401">
<a name="364401"></a>Corby DG. Aspirin in pregnancy: maternal and fetal effects. <i>Pediatrics</i>. 1978;62(2)(suppl):930-937.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/364401/pubmed" id="364401" target="_blank">364401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24741318">
<a name="24741318"></a>Cryer B, Mahaffey KW. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. <i>J Multidiscip Healthc</i>. 2014;7:137-146. doi:10.2147/JMDH.S54324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24741318/pubmed" id="24741318" target="_blank">24741318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15811481">
<a name="15811481"></a>Cryer B, Verlin RG, Cooper SA, et al, “Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Ibuprofen Effects on Thromboxane B2 Concentrations in Aspirin-Treated Healthy Adult Volunteers,” <i>Clin Ther</i>, 2005, 27(2):185-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/15811481/pubmed" id="15811481" target="_blank">15811481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cucchiara.1">
<a name="Cucchiara.1"></a>Cucchiara BL, Messé SR. Long-term antithrombotic therapy for the secondary prevention of ischemic stroke. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28418802">
<a name="28418802"></a>Datta P, Rewers-Felkins K, Kallem RR, Baker T, Hale TW. Transfer of low dose aspirin into human milk. <i>J Hum Lact</i>. 2017;33(2):296-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/28418802/pubmed" id="28418802" target="_blank">28418802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34581729">
<a name="34581729"></a>Davidson KW, Barry MJ, Mangione CM, et al; US Preventive Services Task Force (USPSTF). Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force recommendation statement. <i>JAMA</i>. 2021;326(12):1186-1191. doi:10.1001/jama.2021.14781<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/34581729/pubmed" id="34581729" target="_blank">34581729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10177739">
<a name="10177739"></a>Department of Health and Human Services, Food and Drug Administration. Labeling for Oral and Rectal Over-the-Counter Drug Products Containing Aspirin and Nonaspirin Salicylates; Reye's Syndrome Warning; Final Rule, (29 CFR Part 201). <i>Fed Regist</i>. April 17, 2003: 18861-18869.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/10177739/pubmed" id="10177739" target="_blank">10177739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21834936">
<a name="21834936"></a>Doña I, Blanca-López N, Jagemann LR, et al. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. <i>Allergy</i>. 2011;66(11):1428-1433. doi:10.1111/j.1398-9995.2011.02684.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/21834936/pubmed" id="21834936" target="_blank">21834936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pai.2018">
<a name="Pai.2018"></a>Douketis JD. Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 16, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35964704">
<a name="35964704"></a>Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. <i>Chest</i>. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/35964704/pubmed" id="35964704" target="_blank">35964704</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Durlaza (aspirin) [prescribing information]. North Haven, CT: New Haven Pharmaceuticals; September 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315278">
<a name="22315278"></a>Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012:141(2)(suppl):e89S-e119S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22315278/pubmed" id="22315278" target="_blank">22315278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3796033">
<a name="3796033"></a>el Makhlouf A, Friedli B, Oberhänsli I, et al. Prosthetic Heart Valve Replacement in Children: Results and Follow-up of 273 Patients. <i>J Thorac Cardiovasc Surg</i>. 1987;93(1):80-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/3796033/pubmed" id="3796033" target="_blank">3796033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Export.DOR">
<a name="Export.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fairman.2019b">
<a name="Fairman.2019b"></a>Fairman RM. Carotid endarterectomy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10468077">
<a name="10468077"></a>Feldman M, Cryer B. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. <i>Am J Cardiol</i>. 1999;84(4):404-409.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/10468077/pubmed" id="10468077" target="_blank">10468077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11172556">
<a name="11172556"></a>Fernandez JS, Sadaniantz A. Medical and revascularization management in acute coronary syndrome in renal patients. <i>Semin Nephrol</i>. 2001;21(1):25-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/11172556/pubmed" id="11172556" target="_blank">11172556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25070666">
<a name="25070666"></a>Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation</i>. 2014;130(19):1749-1767. doi:10.1161/CIR.0000000000000095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25070666/pubmed" id="25070666" target="_blank">25070666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons [published correction appears in <i>Circulation</i>. 2014;129(16):e463]. <i>Circulation.</i> 2012;126(25):e354-e471. doi:10.1161/CIR.0b013e318277d6a0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7214793">
<a name="7214793"></a>Findlay JW, DeAngelis RL, Kearney MF, Welch RM, Findlay JM. Analgesic drugs in breast milk and plasma. <i>Clin Pharmacol Ther</i>. 1981;29(5):625-633.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/7214793/pubmed" id="7214793" target="_blank">7214793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085962">
<a name="25085962"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):2215-2245. doi:10.1161/CIR.0000000000000105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25085962/pubmed" id="25085962" target="_blank">25085962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20966421">
<a name="20966421"></a>Furie KL, Kasner SE, Adams RJ, et al; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke.</i> 2011;42(1):227-276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/20966421/pubmed" id="20966421" target="_blank">20966421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31025592">
<a name="31025592"></a>García Rodríguez LA, Lanas A, Soriano-Gabarró M, Cea Soriano L. Low-dose aspirin and risk of upper/lower gastrointestinal bleeding by bleed severity: a cohort study with nested case-control analysis using primary care electronic health records from the United Kingdom. <i>Ann Med</i>. 2019;51(2):182-192. doi:10.1080/07853890.2019.1591635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31025592/pubmed" id="31025592" target="_blank">31025592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-235394">
<a name="235394"></a>Garrettson LK, Procknal JA, Levy G. Fetal acquisition and neonatal elimination of a large amount of salicylate. Study of a neonate whose mother regularly took therapeutic doses of aspirin during pregnancy. <i>Clin Pharmacol Ther</i>. 1975;17(1):98-103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/235394/pubmed" id="235394" target="_blank">235394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18466797">
<a name="18466797"></a>Gasparyan AY, Watson T, Lip GYH. The role of aspirin in cardiovascular prevention; implications of aspirin resistance. <i>Am J Coll Cardiol</i>. 2008;51(9):1829-1843.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/18466797/pubmed" id="18466797" target="_blank">18466797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27840333">
<a name="27840333"></a>Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Circulation. </i>2017;135(12):e791-e792]. <i>Circulation</i>. 2017;135(12):e726-e779. doi:10.1161/CIR.0000000000000471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/27840333/pubmed" id="27840333" target="_blank">27840333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27747582">
<a name="27747582"></a>Giancane G, Consolaro A, Lanni S, Davì S, Schiappapietra B, Ravelli A. Juvenile idiopathic arthritis: diagnosis and treatment. <i>Rheumatol Ther</i>. 2016;3(2):187-207. doi:10.1007/s40744-016-0040-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/27747582/pubmed" id="27747582" target="_blank">27747582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24226806">
<a name="24226806"></a>Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2013;128(24):2622-2703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24226806/pubmed" id="24226806" target="_blank">24226806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35257507">
<a name="35257507"></a>Gorelik M, Chung SA, Ardalan K, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of Kawasaki disease. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(4):538-548. doi:10.1002/acr.24838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/35257507/pubmed" id="35257507" target="_blank">35257507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17224480">
<a name="17224480"></a>Grines CL, Bonow RO, Casey DE, et al. AHA/ACC/SCAI/ACS/ADA Science Advisory, Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents. A Science Advisory From the American Heart Association, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association With Representation from the American College of Physicians. <i>Circulation</i>. 2007;115(6):813-818. <a href="http://circ.ahajournals.org/cgi/content/full/115/6/813" target="_blank">http://circ.ahajournals.org/cgi/content/full/115/6/813</a>. doi:10.1161/CIRCULATIONAHA.106.180944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/17224480/pubmed" id="17224480" target="_blank">17224480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12651041">
<a name="12651041"></a>Gum PA, Kottke-Marchant K, Welsh PA, et al. A Prospective, Blinded Determination of the Natural History of Aspirin Resistance Among Stable Patients With Cardiovascular Disease. <i>J Am Coll Cardiol</i>. 2003;41(6):961-965.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/12651041/pubmed" id="12651041" target="_blank">12651041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2)(suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31237645">
<a name="31237645"></a>Hahn JY, Song YB, Oh JH, et al; SMART-CHOICE Investigators. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. <i>JAMA</i>. 2019;321(24):2428-2437. doi:10.1001/jama.2019.8146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31237645/pubmed" id="31237645" target="_blank">31237645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32358837">
<a name="32358837"></a>Hamulyák EN, Scheres LJ, Marijnen MC, Goddijn M, Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. <i>Cochrane Database Syst Rev</i>. 2020;5(5):CD012852. doi:10.1002/14651858.CD012852.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/32358837/pubmed" id="32358837" target="_blank">32358837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33687789">
<a name="33687789"></a>Hamulyák EN, Scheres LJJ, Goddijn M, Middeldorp S. Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome-What is the evidence? <i>J Thromb Haemost</i>. 2021;19(5):1174-1185. doi:10.1111/jth.15290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/33687789/pubmed" id="33687789" target="_blank">33687789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-112475">
<a name="112475"></a>Harter HR, Burch JW, Majerus PW, et al. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. <i>New Eng J Med</i>. 1979;301(11):577-579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/112475/pubmed" id="112475" target="_blank">112475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35118829">
<a name="35118829"></a>Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology (ACR) clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 3. <i>Arthritis Rheumatol</i>. Published online February 3, 2022. doi:10.1002/art.42062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/35118829/pubmed" id="35118829" target="_blank">35118829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hennekens.1">
<a name="Hennekens.1"></a>Hennekens CH. Aspirin for the secondary prevention of atherosclerotic cardiovascular disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8546133">
<a name="8546133"></a>Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. <i>Am J Kidney Dis</i>. 1996;27(1):162-165.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/8546133/pubmed" id="8546133" target="_blank">8546133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29357887">
<a name="29357887"></a>Hinze CH, Holzinger D, Lainka E, et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. <i>Pediatr Rheumatol Online J</i>. 2018;16(1):7. doi:10.1186/s12969-018-0224-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/29357887/pubmed" id="29357887" target="_blank">29357887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22236727">
<a name="22236727"></a>Hoyte FC, Weber RW, Katial RK. Pancreatitis as a novel complication of aspirin therapy in patients with aspirin-exacerbated respiratory disease. <i>J Allergy Clin Immunol</i>. 2012;129(6):1684-1686. doi:10.1016/j.jaci.2011.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22236727/pubmed" id="22236727" target="_blank">22236727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26369688">
<a name="26369688"></a>Hsu PI, Tsai TJ. Epidemiology of upper gastrointestinal damage associated with low-dose aspirin. <i>Curr Pharm Des</i>. 2015;21(35):5049-5055. doi:10.2174/1381612821666150915104800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26369688/pubmed" id="26369688" target="_blank">26369688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31081871">
<a name="31081871"></a>Huang WY, Saver JL, Wu YL, Lin CJ, Lee M, Ovbiagele B. Frequency of intracranial hemorrhage with low-dose aspirin in individuals without symptomatic cardiovascular disease: a systematic review and meta-analysis. <i>JAMA Neurol</i>. 2019;76(8):906-914. doi:10.1001/jamaneurol.2019.1120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31081871/pubmed" id="31081871" target="_blank">31081871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imazio.1">
<a name="Imazio.1"></a>Imazio M. Acute pericarditis: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15028364">
<a name="15028364"></a>Imazio M, Demichelis B, Parrini I, et al. Day-hospital treatment of acute pericarditis. <i>J Am Coll Cardiol.</i> 2004;43(6):1042-1046.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/15028364/pubmed" id="15028364" target="_blank">15028364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9174558">
<a name="9174558"></a>International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. <i>Lancet</i>. 1997;349(9065):1569-1581.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/9174558/pubmed" id="9174558" target="_blank">9174558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jamali.1">
<a name="Jamali.1"></a>Jamali F, Keshavarz E. Salicylate excretion in breast milk. <i>Int J Pharm</i>. 1981;8:285-290.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23370205">
<a name="23370205"></a>Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. <i>Stroke</i>. 2013;44(3):870-947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/23370205/pubmed" id="23370205" target="_blank">23370205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jim.1">
<a name="Jim.1"></a>Jim J, Fairman MD. Percutaneous carotid artery stenting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 15, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jim.2">
<a name="Jim.2"></a>Jim J. Transcarotid artery revascularization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 15, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32668111">
<a name="32668111"></a>Johnston SC, Amarenco P, Denison H, et al; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. <i>N Engl J Med</i>. 2020;383(3):207-217. doi:10.1056/NEJMoa1916870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/32668111/pubmed" id="32668111" target="_blank">32668111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25986310">
<a name="25986310"></a>Juurlink DN, Gosselin S, Kielstein JT, et al; EXTRIP Workgroup. Extracorporeal treatment for salicylate poisoning: systematic review and recommendations from the EXTRIP Workgroup. <i>Ann Emerg Med</i>. 2015;66(2):165-181.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25986310/pubmed" id="25986310" target="_blank">25986310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29121410">
<a name="29121410"></a>Kalich BA, Allender JE, Hollis IB. Medication management of patients undergoing transcatheter aortic valve replacement. <i>Pharmacotherapy</i>. 2018;38(1):122-138. doi:10.1002/phar.2056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/29121410/pubmed" id="29121410" target="_blank">29121410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27154242">
<a name="27154242"></a>Källén B, Reis M. Ongoing pharmacological management of chronic pain in pregnancy. <i>Drugs</i>. 2016;76(9):915-924.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/27154242/pubmed" id="27154242" target="_blank">27154242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27909874">
<a name="27909874"></a>Kang X, Hong D, Anvari M, Tiboni M, Amin N, Gmora S. Is daily low-dose aspirin safe to take following laparoscopic Roux-en-Y gastric bypass for obesity surgery? <i>Obes Surg</i>. 2017;27(5):1261-1265. doi:10.1007/s11695-016-2462-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/27909874/pubmed" id="27909874" target="_blank">27909874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kannam.1">
<a name="Kannam.1"></a>Kannam JP, Aroesty JM, Gersh BJ. Stable ischemic heart disease: overview of care. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 20, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19103366">
<a name="19103366"></a>Kawakami T, Fujita A, Takeuchi S, Muto S, Soma Y. Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease. <i>J Am Acad Dermatol</i>. 2009;60(1):146-149. doi:10.1016/j.jaad.2008.07.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/19103366/pubmed" id="19103366" target="_blank">19103366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24215903">
<a name="24215903"></a>Kawamura N, Ito Y, Sasaki M, et al. Low-dose aspirin-associated upper gastric and duodenal ulcers in Japanese patients with no previous history of peptic ulcers. <i>BMC Res Notes</i>. 2013;6:455. doi:10.1186/1756-0500-6-455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24215903/pubmed" id="24215903" target="_blank">24215903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15806502">
<a name="15806502"></a>K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. <i>Am J Kidney Dis</i>. 2005;45(4)(suppl 3):S1-S153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/15806502/pubmed" id="15806502" target="_blank">15806502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17276798">
<a name="17276798"></a>KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. <i>Am J Kidney Dis</i>. 2007;49(2)(suppl 2):S12-S154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/17276798/pubmed" id="17276798" target="_blank">17276798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26867832">
<a name="26867832"></a>Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report [published correction appears in <i>Chest</i>. 2016;150(4):988]. <i>Chest</i>. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26867832/pubmed" id="26867832" target="_blank">26867832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31381464">
<a name="31381464"></a>Key NS, Khorana AA, Kuderer NM, et al. A. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol.</i> 2020;38(5):496-520. doi:10.1200/JCO.19.01461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31381464/pubmed" id="31381464" target="_blank">31381464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24587953">
<a name="24587953"></a>Kim YJ, Lim KH, Kim MY, et al. Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity. <i>Allergy Asthma Immunol Res</i>. 2014;6(2):156-162. doi:10.4168/aair.2014.6.2.156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24587953/pubmed" id="24587953" target="_blank">24587953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32543684">
<a name="32543684"></a>Kim BK, Hong SJ, Cho YH, et al; TICO Investigators. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. <i>JAMA</i>. 2020;323(23):2407-2416. doi:10.1001/jama.2020.7580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/32543684/pubmed" id="32543684" target="_blank">32543684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23633350">
<a name="23633350"></a>Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. <i>Cochrane Database Syst Rev</i>. 2013;2013(4):CD008041. doi:10.1002/14651858.CD008041.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/23633350/pubmed" id="23633350" target="_blank">23633350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31545385">
<a name="31545385"></a>Klar H, Sotošek N, Šelb J, Košnik M. Selective hypersensitivity to a single nonsteroidal anti-inflammatory drug. <i>Acta Dermatovenerol Alp Pannonica Adriat</i>. 2019;28(3):97-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31545385/pubmed" id="31545385" target="_blank">31545385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34024117">
<a name="34024117"></a>Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2021;52(7):e364-e467. doi:10.1161/STR.0000000000000375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/34024117/pubmed" id="34024117" target="_blank">34024117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17609236">
<a name="17609236"></a>Knowles SR, Drucker AM, Weber EA, Shear NH. Management options for patients with aspirin and nonsteroidal antiinflammatory drug sensitivity. <i>Ann Pharmacother</i>. 2007;41(7):1191-1200. doi:10.1345/aph.1K023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/17609236/pubmed" id="17609236" target="_blank">17609236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19155962">
<a name="19155962"></a>Koren G. Hearing loss in a woman on aspirin: the silent pharmacokinetic parameter. <i>Ther Drug Monit</i>. 2009;31(1):1-2. doi:10.1097/FTD.0b013e3181951ed9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/19155962/pubmed" id="19155962" target="_blank">19155962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30216468">
<a name="30216468"></a>Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper. <i>Allergy</i>. 2019;74(1):28-39. doi:10.1111/all.13599<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/30216468/pubmed" id="30216468" target="_blank">30216468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117484">
<a name="24117484"></a>Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. <i>Allergy</i>. 2013;68(10):1219-1232. doi:10.1111/all.12260<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24117484/pubmed" id="24117484" target="_blank">24117484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21631520">
<a name="21631520"></a>Kowalski ML, Makowska JS, Blanca M, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. <i>Allergy</i>. 2011;66(7):818-829. doi:10.1111/j.1398-9995.2011.02557.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/21631520/pubmed" id="21631520" target="_blank">21631520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25749768">
<a name="25749768"></a>Kowalski ML, Makowska JS. Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice? <i>Allergy Asthma Immunol Res</i>. 2015;7(4):312-320. doi:10.4168/aair.2015.7.4.312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25749768/pubmed" id="25749768" target="_blank">25749768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25679302">
<a name="25679302"></a>Kulik A, Ruel M, Jneid H, et al; American Heart Association Council on Cardiovascular Surgery and Anesthesia. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131(10):927-964. doi:10.1161/CIR.0000000000000182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25679302/pubmed" id="25679302" target="_blank">25679302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33250267">
<a name="33250267"></a>Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2021;77(5):629-658. doi:10.1016/j.jacc.2020.09.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/33250267/pubmed" id="33250267" target="_blank">33250267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31609071">
<a name="31609071"></a>Kuno T, Takagi H, Sugiyama T, et al. Antithrombotic strategies after transcatheter aortic valve implantation: insights from a network meta-analysis [published online October 14, 2019]. <i>Catheter Cardiovasc Interv</i>. doi:10.1002/ccd.28498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31609071/pubmed" id="31609071" target="_blank">31609071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26506270">
<a name="26506270"></a>Kwolek CJ, Jaff MR, Leal JI, et al. Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal. <i>J Vasc Surg</i>. 2015;62(5):1227-1234. doi:10.1016/j.jvs.2015.04.460<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26506270/pubmed" id="26506270" target="_blank">26506270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19585463">
<a name="19585463"></a>Lafrance JP, Miller DR. Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. <i>Pharmacoepidemiol Drug</i>
<i>Saf</i>. 2009;18(10):923-931. doi:10.1002/pds.1798<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/19585463/pubmed" id="19585463" target="_blank">19585463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28483309">
<a name="28483309"></a>Laidlaw TM, Cahill KN. Current knowledge and management of hypersensitivity to aspirin and NSAIDs. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):537-545. doi:10.1016/j.jaip.2016.10.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/28483309/pubmed" id="28483309" target="_blank">28483309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14711910">
<a name="14711910"></a>Landolfi R, Marchioli R, Kutti J, et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. <i>N Engl J Med</i>. 2004;350(2):114-124. doi:10.1056/NEJMoa035572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/14711910/pubmed" id="14711910" target="_blank">14711910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315273">
<a name="22315273"></a>Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e601S-e636S. doi:10.1378/chest.11-2302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22315273/pubmed" id="22315273" target="_blank">22315273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21835953">
<a name="21835953"></a>Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood</i>. 2012;119(4):933-939; quiz 1093. doi:10.1182/blood-2011-03-344333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/21835953/pubmed" id="21835953" target="_blank">21835953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34895950">
<a name="34895950"></a>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/34895950/pubmed" id="34895950" target="_blank">34895950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8481259">
<a name="8481259"></a>LeBlanc JG, Sett SS, Vince DJ. Antiplatelet Therapy in Children With Left-Sided Mechanical Prostheses. <i>Eur J Cardiothorac Surg</i>. 1993;7(4):211-215.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/8481259/pubmed" id="8481259" target="_blank">8481259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20961243">
<a name="20961243"></a>Leon MB, Smith CR, Mack M, et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. <i>N Engl J Med</i>. 2010;363(17):1597-1607. doi:10.1056/NEJMoa1008232<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/20961243/pubmed" id="20961243" target="_blank">20961243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27040324">
<a name="27040324"></a>Leon MB, Smith CR, Mack MJ, et al; PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. <i>N Engl J Med</i>. 2016;374(17):1609-1620. doi:10.1056/NEJMoa1514616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/27040324/pubmed" id="27040324" target="_blank">27040324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2735989">
<a name="2735989"></a>Leventhal LJ, Kuritsky L, Ginsburg R, Bomalaski JS. Salicylate-induced rhabdomyolysis. <i>Am J Emerg Med</i>. 1989;7(4):409-410. doi:10.1016/0735-6757(89)90049-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/2735989/pubmed" id="2735989" target="_blank">2735989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-724339">
<a name="724339"></a>Levy G. Clinical Pharmacokinetics of Aspirin. <i>Pediatrics</i>. 1978;62(5, pt 2)(suppl):867-872.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/724339/pubmed" id="724339" target="_blank">724339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1157445">
<a name="1157445"></a>Levy G, Procknal JA, Garrettson LK. Distribution of salicylate between neonatal and maternal serum at diffusion equilibrium. <i>Clin Pharmacol Ther</i>. 1975;18(2):210-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/1157445/pubmed" id="1157445" target="_blank">1157445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LeWinter.1">
<a name="LeWinter.1"></a>LeWinter MM. Pericardial complications of myocardial infarction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25475899">
<a name="25475899"></a>Li L, Li W, Chen CZ, Yi ZH, Zhou YY. Is aspirin use associated with age-related macular degeneration? A meta-analysis. <i>J Clin Pharm Ther</i>. 2015;40(2):144-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25475899/pubmed" id="25475899" target="_blank">25475899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15836564">
<a name="15836564"></a>Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN. Aspirin is efficacious for the treatment of acute migraine. <i>Headache</i>. 2005;45(4):283-292. doi:10.1111/j.1526-4610.2005.05065.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/15836564/pubmed" id="15836564" target="_blank">15836564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2868341">
<a name="2868341"></a>Livio M, Benigni A, Viganò G, Mecca G, Remuzzi G. Moderate doses of aspirin and risk of bleeding in renal failure. <i>Lancet</i>. 1986;1(8478):414-416. doi:10.1016/s0140-6736(86)92372-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/2868341/pubmed" id="2868341" target="_blank">2868341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33570602">
<a name="33570602"></a>Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. <i>Blood Adv.</i> 2021;5(4):927-974. doi:10.1182/bloodadvances.2020003442<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/33570602/pubmed" id="33570602" target="_blank">33570602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19076101">
<a name="19076101"></a>Maalouf R, Mosley M, James Kallail K, Kramer KM, Kumar G. A comparison of salicylic acid levels in normal subjects after rectal versus oral dosing. <i>Acad Emerg Med</i>. 2009;16(2):157-161. doi:10.1111/j.1553-2712.2008.00318.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/19076101/pubmed" id="19076101" target="_blank">19076101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12598144">
<a name="12598144"></a>MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. <i>Lancet</i>. 2003;361(9357):573-574. doi:10.1016/s0140-6736(03)12509-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/12598144/pubmed" id="12598144" target="_blank">12598144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12010380">
<a name="12010380"></a>MacGregor EA, Dowson A, Davies PT. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. <i>Headache</i>. 2002;42(4):249-255. doi:10.1046/j.1526-4610.2002.02076.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/12010380/pubmed" id="12010380" target="_blank">12010380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. <i>Breastfeed Med</i>. 2018;13(3):164-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25399658">
<a name="25399658"></a>Mauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. <i>N Engl J Med</i>. 2014;371(23):2155-2166. doi:10.1056/NEJMoa1409312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25399658/pubmed" id="25399658" target="_blank">25399658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28356445">
<a name="28356445"></a>McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/28356445/pubmed" id="28356445" target="_blank">28356445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11431304">
<a name="11431304"></a>McGovern MC, Glasgow JF, Stewart MC. Lesson of the week: Reye's syndrome and aspirin: lest we forget. <i>BMJ</i>. 2001;322(7302):1591-1592. doi:10.1136/bmj.322.7302.1591<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/11431304/pubmed" id="11431304" target="_blank">11431304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30478826">
<a name="30478826"></a>McMullin MF, Harrison CN, Ali S, et al; BSH Committee. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology guideline. <i>Br J Haematol</i>. 2019;184(2):176-191. doi:10.1111/bjh.15648<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/30478826/pubmed" id="30478826" target="_blank">30478826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30221597">
<a name="30221597"></a>McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. <i>N Engl J Med</i>. 2018;379(16):1509-1518. doi:10.1056/NEJMoa1805819<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/30221597/pubmed" id="30221597" target="_blank">30221597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21802823">
<a name="21802823"></a>Medeiros FB, de Andrade AC, Angelis GA, et al. Bleeding Evaluation During Single Tooth Extraction in Patients With Coronary Artery Disease and Acetylsalicylic Acid Therapy Suspension: A Prospective, Double-Blinded, and Randomized Study. <i>J Oral Maxillofac Surg</i>. 2011;69(12):2949-2955.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/21802823/pubmed" id="21802823" target="_blank">21802823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31556978">
<a name="31556978"></a>Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. <i>N Engl J Med</i>. 2019;381(21):2032-2042. doi:10.1056/NEJMoa1908419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31556978/pubmed" id="31556978" target="_blank">31556978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11520521">
<a name="11520521"></a>Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. <i>Lancet</i>. 2001;358(9281):527-533.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/11520521/pubmed" id="11520521" target="_blank">11520521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25355838">
<a name="25355838"></a>Meschia JF, Bushnell C, Boden-Albala B, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2014;45(12):3754-832. doi:10.1161/STR.0000000000000046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25355838/pubmed" id="25355838" target="_blank">25355838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26797705">
<a name="26797705"></a>Mitrov-Winkelmolen L, van Buul-Gast MW, Swank DJ, Overdiek HWPM, van Schaik RHN, Touw DJ. The effect of Roux-en-Y gastric bypass surgery in morbidly obese patients on pharmacokinetics of (acetyl)salicylic acid and omeprazole: the ERY-PAO study. <i>Obes Surg</i>. 2016;26(9):2051-2058. doi:10.1007/s11695-016-2065-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26797705/pubmed" id="26797705" target="_blank">26797705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315277">
<a name="22315277"></a>Monagle P, Chan A, Goldenberg NA, et al. Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). <i>Chest</i>. 2012;141(2)(suppl):e737-e801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22315277/pubmed" id="22315277" target="_blank">22315277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21798429">
<a name="21798429"></a>Monagle P, Cochrane A, Roberts R, et al. A Multicenter, Randomized Trial Comparing Heparin/Warfarin and Acetylsalicylic Acid as Primary Thromboprophylaxis for 2 Years after the Fontan Procedure in Children. <i>J Am Coll Cardiol</i>. 2011;58(6):645-651.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/21798429/pubmed" id="21798429" target="_blank">21798429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33493011">
<a name="33493011"></a>Naimi AI, Perkins NJ, Sjaarda LA, et al. The effect of preconception-initiated low-dose aspirin on human chorionic gonadotropin-detected pregnancy, pregnancy loss, and live birth: per protocol analysis of a randomized trial. <i>Ann Intern Med</i>. 2021;174(5):595-601. doi:10.7326/M20-0469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/33493011/pubmed" id="33493011" target="_blank">33493011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. https://www.nice.org.uk/guidance/cg183 Published September 3, 2014. Accessed November 3, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Therapeutic management of hospitalized pediatric patients with multisystem inflammatory syndrome in children (MIS-C) (with discussion on multisystem inflammatory syndrome in adults [MIS-A]). <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-pediatric-patients--therapeutic-management-of-mis-c/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-pediatric-patients--therapeutic-management-of-mis-c/</a>. Updated February 24, 2022. Accessed March 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15574639">
<a name="15574639"></a>Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. <i>Pediatrics</i>. 2004;114(6):1708-1733.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/15574639/pubmed" id="15574639" target="_blank">15574639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Konkle.1">
<a name="Konkle.1"></a>Nkomo VT, Konkle BA. Antithrombotic therapy for surgical bioprosthetic valves and surgical valve repair. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28444860">
<a name="28444860"></a>Norgard NB, Monte SV, Fernandez SF, Ma Q. Aspirin responsiveness changes in obese patients following bariatric surgery. <i>Cardiovasc Ther</i>. 2017;35(4). doi:10.1111/1755-5922.12268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/28444860/pubmed" id="28444860" target="_blank">28444860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32551860">
<a name="32551860"></a>O'Donoghue ML, Murphy SA, Sabatine MS. The safety and efficacy of aspirin discontinuation on a background of a P2Y<sub>12</sub> inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis. <i>Circulation</i>. 2020;142(6):538-545. doi:10.1161/CIRCULATIONAHA.120.046251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/32551860/pubmed" id="32551860" target="_blank">32551860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425. doi:10.1161/CIR.0b013e3182742cf6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Filho.1">
<a name="Filho.1"></a>Oliveira-Filho J, Mullen MT. Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9759151">
<a name="9759151"></a>Østensen M. Nonsteroidal Anti-inflammatory Drugs During Pregnancy. <i>Scand J Rheumatol Suppl</i>. 1998;107:128-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/9759151/pubmed" id="9759151" target="_blank">9759151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28063810">
<a name="28063810"></a>Otto CM, Kumbhani DJ, Alexander KP, et al. 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. <i>J Am Coll Cardiol</i>. 2017;69(10):1313-1346. doi:10.1016/j.jacc.2016.12.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/28063810/pubmed" id="28063810" target="_blank">28063810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332150">
<a name="33332150"></a>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/33332150/pubmed" id="33332150" target="_blank">33332150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20458022">
<a name="20458022"></a>Paikin JS, Wright DS, Crowther MA, Mehta SR, Eikelboom JW. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. <i>Circulation</i>. 2010;121(18):2067-2070. doi:10.1161/CIRCULATIONAHA.109.924944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/20458022/pubmed" id="20458022" target="_blank">20458022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5819427">
<a name="5819427"></a>Palmisano PA, Cassady G. Salicylate exposure in the perinate. <i>JAMA</i>. 1969;209(4):556-558.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/5819427/pubmed" id="5819427" target="_blank">5819427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21282540">
<a name="21282540"></a>Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. <i>J Clin Oncol.</i> 2011;29(8):986-993. doi:10.1200/JCO.2010.31.6844<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/21282540/pubmed" id="21282540" target="_blank">21282540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22234683">
<a name="22234683"></a>Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. <i>Blood</i>. 2012;119(15):3595-3603. doi:10.1182/blood-2011-06-359224<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22234683/pubmed" id="22234683" target="_blank">22234683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24634525">
<a name="24634525"></a>Poh J, Knowles S. Safety of 5-aminosalicylic acid derivatives in patients with sensitivity to acetylsalicylic acid and nonsteroidal anti-inflammatory drugs. <i>Can J Hosp Pharm</i>. 2014;67(1):35-38. doi:10.4212/cjhp.v67i1.1318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24634525/pubmed" id="24634525" target="_blank">24634525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31111484">
<a name="31111484"></a>Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. <i>Int J Gynaecol Obstet</i>. 2019;145(suppl 1):1-33. doi:10.1002/ijgo.12802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31111484/pubmed" id="31111484" target="_blank">31111484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31662037">
<a name="31662037"></a>Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31662037/pubmed" id="31662037" target="_blank">31662037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24512654">
<a name="24512654"></a>Puskas J, Gerdisch M, Nichols D, et al; PROACT Investigators. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized On-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. <i>J Thorac Cardiovasc Surg.</i> 2014;147(4):1202-1210; discussion 1210-1211. doi:10.1016/j.jtcvs.2014.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24512654/pubmed" id="24512654" target="_blank">24512654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16118317">
<a name="16118317"></a>Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. <i>Blood</i>. 2005;106(13):4050-4053. doi:10.1182/blood-2005-07-2817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/16118317/pubmed" id="16118317" target="_blank">16118317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28304219">
<a name="28304219"></a>Reardon MJ, Van Mieghem NM, Popma JJ, et al; SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. <i>N Engl J Med</i>. 2017;376(14):1321-1331. doi:10.1056/NEJMoa1700456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/28304219/pubmed" id="28304219" target="_blank">28304219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RHDAustralia.1">
<a name="RHDAustralia.1"></a>RHD Australia. The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. 3rd edition. https://www.rhdaustralia.org.au/system/files/fileuploads/arf_rhd_guidelines_3rd_edition_final.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31021516">
<a name="31021516"></a>Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. <i>Arthritis Care Res (Hoboken)</i>. 2019;71(6):717-734. doi:10.1002/acr.23870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31021516/pubmed" id="31021516" target="_blank">31021516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24339215">
<a name="24339215"></a>Ringold S, Weiss PF, Colbert RA, et al. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2014;66(7):1063-1072. doi:10.1002/acr.22259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24339215/pubmed" id="24339215" target="_blank">24339215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28657417">
<a name="28657417"></a>Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. <i>N Engl J Med.</i> 2017;377(7):613-622. doi:10.1056/NEJMoa1704559<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/28657417/pubmed" id="28657417" target="_blank">28657417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1379157">
<a name="1379157"></a>Rose CD, Doughty RA. Pharmacological management of juvenile rheumatoid arthritis. <i>Drugs</i>. 1992;43(6):849-863. doi:10.2165/00003495-199243060-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/1379157/pubmed" id="1379157" target="_blank">1379157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7016383">
<a name="7016383"></a>Rosenberg J, Benowitz NL, Pond S. Pharmacokinetics of drug overdose. <i>Clin Pharmacokinet</i>. 1981;6(3):161-192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/7016383/pubmed" id="7016383" target="_blank">7016383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20970847">
<a name="20970847"></a>Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials. <i>Lancet</i>. 2010;376(9754):1741-1750. doi:10.1016/S0140-6736(10)61543-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/20970847/pubmed" id="20970847" target="_blank">20970847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7823260">
<a name="7823260"></a>Rymark P, Berntorp E, Nordsjö P, Liedholm H, Melander A, Gennser G. Low-dose aspirin to pregnant women: single dose pharmacokinetics and influence of short term treatment on bleeding time. <i>J Perinat Med</i>. 1994;22(3):205-211.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/7823260/pubmed" id="7823260" target="_blank">7823260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-e809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21544823">
<a name="21544823"></a>Sai Y, Kusaka A, Imanishi K, et al. A randomized, quadruple crossover single-blind study on immediate action of chewed and unchewed low-dose acetylsalicylic acid tablets in healthy volunteers. <i>J Pharm Sci</i>. 2011;100(9):3884-3891. doi:10.1002/jps.22602<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/21544823/pubmed" id="21544823" target="_blank">21544823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33433020">
<a name="33433020"></a>Saldanha IJ, Cao W, Bhuma MR, et al. Management of primary headaches during pregnancy, postpartum, and breastfeeding: a systematic review. <i>Headache</i>. 2021;61(1):11-43. doi:10.1111/head.14041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/33433020/pubmed" id="33433020" target="_blank">33433020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529-556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24668137">
<a name="24668137"></a>Sandercock PA, Counsell C, Tseng MC, Cecconi E. Oral antiplatelet therapy for acute ischaemic stroke. <i>Cochrane Database Syst Rev</i>. 2014;(3):CD000029. doi:10.1002/14651858.CD000029.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24668137/pubmed" id="24668137" target="_blank">24668137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.1">
<a name="Schwedt.1"></a>Schwedt TJ, Garza Ivan. Acute treatment of migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17125112">
<a name="17125112"></a>Segal R, Lubart E, Leibovitz A, Iaina A, Caspi D. Renal effects of low dose aspirin in elderly patients. <i>Isr Med Assoc J</i>. 2006;8(10):679-682.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/17125112/pubmed" id="17125112" target="_blank">17125112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15877994">
<a name="15877994"></a>Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. <i>Am J Cardiol</i>. 2005;95(10):1218-1222. doi:10.1016/j.amjcard.2005.01.049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/15877994/pubmed" id="15877994" target="_blank">15877994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3654744">
<a name="3654744"></a>Serra AJ, McNicholas KW, Olivier HF Jr, et al. The Choice of Anticoagulation in Pediatric Patients With the St. Jude Medical Valve Prostheses. <i>J Cardiovasc Surg</i>. 1987;28(5):588-591.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/3654744/pubmed" id="3654744" target="_blank">3654744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26448875">
<a name="26448875"></a>Shah S, Banh ET, Koury K, Bhatia G, Nandi R, Gulur P. Pain management in pregnancy: multimodal approaches. <i>Pain Res Treat</i>. 2015;2015:987483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26448875/pubmed" id="26448875" target="_blank">26448875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31051121">
<a name="31051121"></a>Shanmugalingam R, Wang X, Münch G, et al. A pharmacokinetic assessment of optimal dosing, preparation, and chronotherapy of aspirin in pregnancy. <i>Am J Obstet Gynecol</i>. 2019;221(3):255.e1-e255.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31051121/pubmed" id="31051121" target="_blank">31051121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36084704">
<a name="36084704"></a>Silver R, Craigo S, Porter F, Osmundson S, Norton ME; Society for Maternal-Fetal Medicine (SMFM). Society for Maternal-Fetal Medicine (SMFM) consult series #64: systemic lupus erythematosus in pregnancy.<i> Am J Obstet Gynecol.</i> 2022:S0002-9378(22)00722-0. doi:10.1016/j.ajog.2022.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/36084704/pubmed" id="36084704" target="_blank">36084704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25156992">
<a name="25156992"></a>Simes J, Becattini C, Agnelli G, et al; INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism). Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. <i>Circulation</i>. 2014;130(13):1062-1071. doi:10.1161/CIRCULATIONAHA.114.008828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25156992/pubmed" id="25156992" target="_blank">25156992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21639811">
<a name="21639811"></a>Smith CR, Leon MB, Mack MJ, et al; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. <i>N Engl J Med</i>. 2011;364(23):2187-2198. doi:10.1056/NEJMoa1103510<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/21639811/pubmed" id="21639811" target="_blank">21639811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1990763">
<a name="1990763"></a>Solymar L, Rao PS, Mardini MK, et al. Prosthetic Valves in Children and Adolescents. <i>Am Heart J</i>. 1991;121(2, pt 1):557-568.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/1990763/pubmed" id="1990763" target="_blank">1990763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10937472">
<a name="10937472"></a>Spigset O, Hagg S. Analgesics and Breast-Feeding: Safety Considerations. <i>Paediatr Drugs</i>. 2000;2(3):223-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/10937472/pubmed" id="10937472" target="_blank">10937472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Steer.2019">
<a name="Steer.2019"></a>Steer A, Gibofsky A. Acute rheumatic fever: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 22, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34352278">
<a name="34352278"></a>Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. <i>Chest</i>. 2021;160(6):e545-e608. doi:10.1016/j.chest.2021.07.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/34352278/pubmed" id="34352278" target="_blank">34352278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3722646">
<a name="3722646"></a>Stevenson DD, Simon RA, Lumry WR, Mathison DA. Adverse reactions to tartrazine. <i>J Allergy Clin Immunol</i>. 1986;78(1 Pt 2):182-191. doi:10.1016/0091-6749(86)90011-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/3722646/pubmed" id="3722646" target="_blank">3722646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30280640">
<a name="30280640"></a>Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. <i>N Engl J Med</i>. 2018;379(24):2307-2318. doi:10.1056/NEJMoa1806640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/30280640/pubmed" id="30280640" target="_blank">30280640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26528445">
<a name="26528445"></a>Summaria F, Giannico MB, Talarico GP, Patrizi R. Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions. <i>Nephrourol Mon</i>. 2015;7(4):e28099.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26528445/pubmed" id="26528445" target="_blank">26528445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26106845">
<a name="26106845"></a>Sverdén E, Mattsson F, Sondén A, et al. Risk factors for marginal ulcer after gastric bypass surgery for obesity: a population-based cohort study. <i>Ann Surg</i>. 2016;263(4):733-737. doi:10.1097/SLA.0000000000001300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26106845/pubmed" id="26106845" target="_blank">26106845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tefferi.1">
<a name="Tefferi.1"></a>Tefferi A. Prognosis and treatment of polycythemia vera and secondary polycythemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 11, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27991718">
<a name="27991718"></a>Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. <i>Am J Hematol</i>. 2017;92(1):94-108. doi:10.1002/ajh.24607<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/27991718/pubmed" id="27991718" target="_blank">27991718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26928755">
<a name="26928755"></a>Terlemez S, Demir F, Bulut Y, et al. DRESS syndrome developed related to acetylsalicylic acid use. <i>Pediatr Allergy Immunol</i>. 2016;27(2):227-230. doi:10.1111/pai.12484<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26928755/pubmed" id="26928755" target="_blank">26928755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6069440">
<a name="6069440"></a>Terragna A, Spirito L. Thrombocytopenic purpura in an infant after administration of acetylsalicylic acid to the wet-nurse. <i>Minerva Pediatr</i>. 1967;19(13):613-616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/6069440/pubmed" id="6069440" target="_blank">6069440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32789114">
<a name="32789114"></a>Terzioğlu K, Sancar Ö, Ekerbiçer HÇ, Öztürk RT, Epöztürk K. Tolerability to paracetamol and preferential COX-2 inhibitors in patients with cross-reactive nonsteroidal anti-inflammatory drugs hypersensitivity. <i>Asia Pac Allergy</i>. 2020;10(3):e29. doi:10.5415/apallergy.2020.10.e29<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/32789114/pubmed" id="32789114" target="_blank">32789114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Turan.1">
<a name="Turan.1"></a>Turan TN, Gutierrez J. Intracranial large artery atherosclerosis: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31479546">
<a name="31479546"></a>Turner JM, Robertson NT, Hartel G, Kumar S. Impact of low-dose aspirin on adverse perinatal outcome: meta-analysis and meta-regression. <i>Ultrasound Obstet Gynecol</i>. 2020;55(2):157-169. doi:10.1002/uog.20859<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31479546/pubmed" id="31479546" target="_blank">31479546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3662653">
<a name="3662653"></a>Unsworth J, d'Assis-Fonseca A, Beswick DT, Blake DR. Serum salicylate levels in a breast fed infant. <i>Ann Rheum Dis</i>. 1987;46(8):638-639.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/3662653/pubmed" id="3662653" target="_blank">3662653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA Drug Safety Communication. MedWatch. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic</a>. Published October 16, 2020. Accessed October 21, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USPSTF.1">
<a name="USPSTF.1"></a>US Preventive Services Task Force (USPSTF). <i>Aspirin for the Prevention of Cardiovascular Disease: Clinical Summary</i>. AHRQ Publication No.09-05129-EF-3, March 2009. Agency for Healthcare Research and Quality, Rockville, MD. http://www.uspreventiveservicestaskforce.org/uspstf09/aspirincvd/aspcvdsum.htm
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35471505">
<a name="35471505"></a>US Preventive Services Task Force (USPSTF); Davidson KW, Barry MJ, Mangione CM, et al. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. <i>JAMA</i>. 2022;327(16):1577-1584. doi:10.1001/jama.2022.4983<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/35471505/pubmed" id="35471505" target="_blank">35471505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26242182">
<a name="26242182"></a>Vannucchi AM, Barbui T, Cervantes F, et al; ESMO Guidelines Committee. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol.</i> 2015;26(suppl 5):v85-v99. doi:10.1093/annonc/mdv203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26242182/pubmed" id="26242182" target="_blank">26242182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32957109">
<a name="32957109"></a>Vásquez LDM, Silva DL, Ramírez LF, Olaya M, Serrano CD. Descriptive analysis of cross-reactive anaphylaxis as a different clinical subtype of nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity. <i>Int Arch Allergy Immunol</i>. 2021;182(2):131-138. doi:10.1159/000510335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/32957109/pubmed" id="32957109" target="_blank">32957109</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vazalore (aspirin) [prescribing information]. Sparta, NJ: PLx Pharma Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30166073">
<a name="30166073"></a>Vranckx P, Valgimigli M, Jüni P, et al; GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet</i>. 2018;392(10151):940-949. doi:10.1016/S0140-6736(18)31858-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/30166073/pubmed" id="30166073" target="_blank">30166073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7723155">
<a name="7723155"></a>Walker MD, Marler JR, Goldstein M, et al; Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. <i>JAMA</i>. 1995;273(18):1421-1428. doi:10.1001/jama.1995.03520420037035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/7723155/pubmed" id="7723155" target="_blank">7723155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19717846">
<a name="19717846"></a>Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med</i>. 2009;361(11):1045-1057. doi:10.1056/NEJMoa0904327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/19717846/pubmed" id="19717846" target="_blank">19717846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31237644">
<a name="31237644"></a>Watanabe H, Domei T, Morimoto T, et al; STOPDAPT-2 Investigators. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. <i>JAMA</i>. 2019;321(24):2414-2427. doi:10.1001/jama.2019.8145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/31237644/pubmed" id="31237644" target="_blank">31237644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11319575">
<a name="11319575"></a>Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. <i>Am J Ther</i>. 2000;7(2):63-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/11319575/pubmed" id="11319575" target="_blank">11319575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30207919">
<a name="30207919"></a>White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. <i>N Engl J Med</i>. 2018;379(11):1060-1070. doi:10.1056/NEJMra1712125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/30207919/pubmed" id="30207919" target="_blank">30207919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17982182">
<a name="17982182"></a>Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med</i>. 2007;357(20):2001-2015. doi:10.1056/NEJMoa0706482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/17982182/pubmed" id="17982182" target="_blank">17982182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668895">
<a name="12668895"></a>Woessner KM. Crossreacting drugs and chemicals. <i>Clin Rev Allergy Immunol</i>. 2003;24(2):149-158. doi:10.1385/CRIAI:24:2:149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/12668895/pubmed" id="12668895" target="_blank">12668895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs.  https://apps.who.int/iris/handle/10665/62435. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Rheumatic fever and rheumatic heart disease: report of a WHO Expert Consultation. Geneva, Switzerland: World Health Organization; 2004. http://www.who.int/cardiovascular_diseases/resources/en/cvd_trs923.pdf. Accessed December 15, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23451245">
<a name="23451245"></a>Ye X, Fu J, Yang Y, Chen S. Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. <i>PLoS One</i>. 2013;8(2):e57578. doi:10.1371/journal.pone.0057578<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/23451245/pubmed" id="23451245" target="_blank">23451245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11519503">
<a name="11519503"></a>Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published corrections appear in <i>N Engl J Med</i>. 2001;345(20):1506; <i>N Engl J Med</i>. 2001;345(23):1716]. <i>N Engl J Med</i>. 2001;345(7):494-502. doi:10.1056/NEJMoa010746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/11519503/pubmed" id="11519503" target="_blank">11519503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28764659">
<a name="28764659"></a>Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. <i>BMC Nephrol</i>. 2017;18(1):256. doi:10.1186/s12882-017-0673-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/28764659/pubmed" id="28764659" target="_blank">28764659</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12829 Version 385.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
